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1. INTRODUCTION TO THE EXPERIMENTAL WORK 
 
The oral cavity is characterized by an environmental moderate temperature and 
high humidity. These features allow the growth of aerobic and anaerobic 
microorganisms which establish a complex ecosystem [1]. 
Saliva is the most important element to maintain balance within the oral 
ecosystem. 
It performs:  
- digestive functions, through the presence of α-amylase; 
- emollient and lubricant functions, thanks to water and mucins; 
- protective functions for dental elements, oral mucosa and 
oesophagus with the contribution from antiviral, antibacterial and 
antifungal substances. 
The crevicular fluid, also known as gingival liquid, is produced by the epithelium 
localized in the gingival sulcus surrounding teeth crowns. It is produced in very small 
amounts by healthy gingiva, but in large amounts when gums are inflammed [2]. It 
performs protective functions for gingival and dental tissues, but it may also be 
involved in the build-up of dental deposits due to its high protein and calcium 
content. 
 
1.1 SALIVARY PRODUCTION 
 
Saliva represents the first digestive juice which is encountered along the 
gastrointestinal tube and is produced by the salivary glands. 
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There are three major salivary glands which lie extra-orally: the parotyd gland, the 
submandibular gland and the sublingual gland. However, buccal, palatine, labial and 
lingual mucosae contain many minor salivary glands. 
The parotyd gland weighs 25-30 g and shows a racemose architecture until 
Stensen’s duct. 
The submandibular gland weighs 8-10 g. Like the parotyd gland, it shows a racemose 
structure to its duct, known as Wharton’s duct. 
The sublingual gland, instead, weighs only 2-3 g and shows multiple ducts, known 
as Rivinus ducts and Bhartolin’s duct. 
Under normal conditions, human beings produce between 800 and 1.500 ml of 
saliva per day, with each gland contributing in a different manner. 
At rest, 70-75% of saliva is mainly produced by the submandibular gland, while only 
20% relies on the parotyd gland. 
When a mechanical or chemycal stimulus acts on the oral cavity, like during chewing 
or after the application of citric acid, over 50% of stimulated saliva comes from the 
parotyd gland, when only 30-45% relies on the submandibular gland.  
At night, the sublingual glands are responsible for the production of 14% of salivary 
amount during sleep. 
Less data have been collected about the contribution of minor salivary glands to 
saliva production, but they are thought to provide constant lubrication of oral 
mucosa during the day, allowing the presence of antimicrobial substances [3](Fig. 
1). 
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Fig.1: Salivary production rates. The salivary glands contribute with different rates 
according to the physiologic state. 
The salivary glands consist of a dead-end duct system, starting from intercalated 
ducts and developing through ducts of higher caliber known as striated ducts to 
secretory ducts. 
In salivary glands, saliva secretion is a two-phase process: firstly, primary saliva is 
produced by acinar cells localized in the secretory pole together with intercalated 
ducts. 
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Secondly, saliva flows along the striated and secretory ducts where it is modified. 
Thus the ionic properties of saliva depend on this mechanism [4]. 
The mechanisms underlying the production of saliva are very complex; a key 
element is certainly represented by an increasing concentration of calcium ions 
within acinar cells when they are stimulated by their associated nerve fibers. 
Both parasympathetic and sympathetic fibers contribute to salivary production. In 
this district the two systems work synergistically and not in opposition like in other 
structures. 
Acetylcholine released by parasympathetic fibers activates the inositol triphosphate 
(IP3) intracellular signaling pathway. The same do α1-adrenergic receptors. On the 
contrary, ß2-adrenergic receptors activate the adenosine monophosphate (AMP) 
pathway, which stimulates genic transcription, post-transcriptional modifications 
and secretory vesicles. Acetylcholine stimulation is more effective in producing 
primary saliva. 
The increased levels of intracellular calcium ions lead to complex mechanisms which 
result in an augmented production of saliva [5]. 
The autonomous nervous system regulates the secretory activity; moreover drugs 
influence on this system may trigger alterations in the composition of salivary liquid 
and in its flow rate. 
The striated ducts are completely impermeable to water and this results in an 
always hypotonic fluid if compared to plasma. 
The central nervous system is involved in a more sophisticated regulation of salivary 
secretion. 
Chewing and gustatory stimulation activate the parasympathetic system through 
the trigeminal lower and upper salivatory nuclei, as well as facial, glossopharyngeal 
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and vagus nerve fibers, while the sympathetic system is activated through the 
superior cervical ganglion. 
Not only do these fibers stimulate the production of saliva in the acinar cells, but 
also activate the myoepithelial cells, which are responsible for ductal contraction. 
The resulting salivary flow does not depend exclusively on the nature of the 
stimulus, but also on its duration and intensity. Sour flavours and frequent chewing 
induce higher salivary flows, but while the parasympathetic stimulation leads to a 
strong watery salivary flow, the sympathetic stimulation triggers a minor stream, 
but enriched in mucins, and therefore particularly viscous [6].  
Salivary secretion is certainly influenced by the bloodstream which reaches the 
glands, because the liquid which makes up saliva derives from the interstitial fluid 
and from the capillary blood. 
Blood vessels caliber is regulated by the autonomous nervous system, consequently 
it can contribute to a greater or minor salivary flow. 
Conditioned reflexes influence the production of saliva. The most famous 
experiment in this field was carried out by Ivan Pavlov on dogs at the end of the 
nineteenth century. Conditioned reflexes are those actions or feelings acquired as 
the result of experience to a specific situation or stimulus. 
Associative cortices allow a smell or a memory to induce the production of saliva 
thanks to a pairing association, without the real presence of a stimulus inside the 
mouth. 
Emotional and affective attitudes are strictly related to conditioned reflexes. This 
feature  explains how anxiety or stress may lead to a diminuished salivary secretion 
or to an altered  salivary composition. 
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Psychiatric diseases and disorders are known to be linked to xerostomia, which is 
defined as the sensation of dry mouth in the presence or absence of a lower salivary 
flow (Fig.2). 
 
 
Fig.2: control of salivary secretion by nerves. Parasympathetic efferent fibers are 
coloured in blue, while sympathetic fibers are coloured in red (from Proctor GB 
[7]) 
 
The first study described in this dissertation, entitled “Low basal salivary flow and 
Burning Mouth Syndrome: new evidence in this enigmatic pathology”, investigates 
the role of this very common psychosomatic and neuropathic disorder of the oral 
cavity in the alteration of salivary flow rates and volumes brought about by strong 
emotional disorders linked to the disease. 
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1.2 SALIVARY COMPOSITION 
 
The salivary fluid is made up of two components: a serous secretion and a mixed 
secretion. 
The serous secretion is enriched in water and α-amilase (ptyalin), the enzyme 
produced by the parotyd gland and which is responsible for the digestion of 
starches. 
The mixed secretion, both serous and mucous, is produced by the submandibular 
and sublingual glands and it is very viscous. The key element in this component is 
mucin, therefore the secretion is responsible for protective and lubricant functions 
on oral mucosae [1]. 
Each gland produces its own saliva, thus the result is a mixed saliva, with the 
addition of flaking cells, white blood cells and bacteria. The salivary liquid is always 
hypotonic if compared to blood, even when the composition is altered by an 
increased salivary flow rate. 
A group of organic compounds and electrolytes can be recognized inside the salivary 
fluid.  
The most important organic particles that can be detected in saliva are the proteins 
secreted by acinar and ductal cells. There are several tens of proteins varying from 
a few kDa to even more than 1000 kDa of weight. The liquid can reach the level of 
2,2 mg/ml of proteins, but it is always less than 60-80 mg/ml detected in blood.  
Among the most important proteic compounds there are: 
- Cortisol, a glycoprotein produced by adrenal glands. Its concentration 
in saliva ranges between 10 and 20 nM. Under a stressful condition, 
salivary cortisol can reach a concentration of 30 nM, thus measuring 
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the presence of this hormone in saliva may help to better understand 
the presence of underlying stressful conditions or events in patients’ 
life, avoiding blood collection; 
- Sexual hormones are present in saliva and they may be monitorized 
during pregnancy; 
- Glucose shows concentration values less than 0,1 nM, but in non-
compensated diabetic patients values may rise up to 1 nM, and this 
explains how dental caries and periodontitis are sensibly frequent in 
diabetic patients; 
- Urea, which is a catabolyc product of proteins, shows a concentration 
of 2-4 nM, but in renal failure it can reach values over 85 nM; 
- AB0 blood antigen groups may be used for forensic medicine. 
Among the electrolytes sodium, chlorine, calcium and bicarbonate show higher 
values when the salivary flow rate is increased, as opposed to what potassium and 
phosphate do. It should be remembered that the circadian rhythm influences 
salivary composition [8]. 
 
1.3 SALIVARY FUNCTIONS 
 
Saliva performs a lot of important functions that are essential for the maintenance 
of oral health. Most of these functions depend on the interaction between saliva 
and oral surfaces of varying texture and polarity.  
 
The first important role that saliva plays in the oral cavity is the maintenance of 
good hygienic conditions in oral tissues. 
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This function is performed thanks to the presence of different molecules: 
- Thyocianate ions;  
- Lysozyme and other enzymes, which mainly attack bacteria and allow 
tyocianate ions to enter bacterial cells leading to their destruction; 
- Antibodies; 
- Growth factors and cytokines. 
In addition, the salivary flow washes oral mucosae continuosly and flushes away 
oral microorganisms and food debris. This ability together with swallowing is 
known as oral clearance [9]. 
 
Another important function of saliva is its buffering capacity.  
Salivary normal pH values are 6.0-7.5 and these values are maintained by 
different buffering systems. When pH values decrease to 5.0-5.5, dental health 
is jeopardized since bacterial fermentation and tooth decay can start.  
The three buffering systems described in saliva are: 
- the bicarbonate buffering system; 
- the phosphates buffering system; 
- the proteins buffering system. 
 
Salivary proteins play an important role in several functions. 
Proteins together certainly determine salivary viscosity and consistency, but 
some specific proteins perform specific functions: 
- Digestive functions: serous cells in parotyd and submandibular glands 
secrete salivary α-amilase after parasympathetic stimulation. The 
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enzyme is responsible for the degradation of starches and 1-4 
glycoside bond in general. It is a very important enzyme, which is 
degradated in the stomach, highlighting thus the fundamental role of 
saliva in digestion. 
- Lubricant functions: two types of mucins can be found in human 
saliva and they form a gelatinous layer. G1 mucin weighs more than 
1.000 kDa and it is the biggest protein in saliva. It is secreted by acinar 
cells in the submandibular and sublingual glands and also by labial 
and palatine glands. G2 mucin shows a low molecular weigh, 150-200 
kDa, and is produced by the serous cells of many glands, with the 
exception of parotyd glands [10]. 
- Calcium homeostasis: human saliva is generally supersatured with 
hydroxyapatite and other calcium phosphate salts. The calcium 
binding protein amount markedly varies between healthy patients 
and patients affected by dental caries. Statherin, a small 4-5 kDa 
protein secreted by acinar cells, inhibits formation of aggregates and 
prevents intraductal calcification and tartar formation. Proline-rich 
proteins (PRPs) also inhibit the formation of aggregates. They account 
for 30% of proteic formation in submandibular and parotyd glands. 
- Catalysing the formation of carbonic acid: carbonic anhydrase is an 
enzyme which catalyzes carbon dioxide into carbonic acid. The VI 
isoform known as gustin is a zinc-containing metalloprotein which 
weighs 37 kDa and represents 3% of human salivary proteins. It is also 
a growth factor for taste buds. 
 
Special attention should be devoted to antibacterial functions. 
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There are many antibacterial, antiviral and antifungal agents in 
human saliva. An alteration in their composition or functions may 
explain how several subjects are more susceptible to infections than 
others. 
Immunoglobulins A are large hydrophilic proteins (380 kDa) produced 
by plasma cells first and then modified and secreted by acinar and 
ductal cells. Labial glands are highly specialized in producing IgAs, 
which represent strong antibacterial agents because of their 
interaction with mucins and aggregated bacteria. 
Lysozyme, which weighs about 14 kDa, lyses Gram-positive walls. 
Lactoferrin is instead a larger protein (75 kDa) and it binds to iron, 
taking away this precious element from bacterial enzymatic  
functions. 
Histatins are small peptides (3-4 kDa) mainly secreted by parotyd 
glands and are especially effective against Candida albicans, 
Streptococcus mutans and Porhyromonas gingivalis. 
Peroxydase is another enzyme which catalyzes oxydation of 
tyocyanate into isocyanate thus blocking bacterial metabolism. 
Antimicrobial peptides (AMPs) are small cathyonic peptides of less 
than 100 amino acids that are found in host defense settings, and that 
have antimicrobial activity at physiological concentrations. They can 
be divided into cathelicidin LL-37, α-defensins and ß-defensins. First 
described in neutrophils and Paneth cells, they have been recently 
detected in saliva and epithelial cells [11]. 
Furthermore, it has been shown than AMPs participate in 
immunomodulation, so an alteration in their quantity may be related 
to the pathogenesis of several infective or autoimmune disease [12]. 
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The second study which is included in this dissertation, “Human ß2-
defensins in Oral Lichen Planus and Burning Mouth Syndrome”, 
investigates if the expression of defensins may play a statistically 
significant role in the pathogenesis of these oral pathologies. 
 
 
Other proteins show multiple functions, like cystatins, which are endogenous 
proteases inhibitors and immunomodulatory agents. 
Besides, many proteins coming from the bloodstream may be found in saliva, like 
albumins, Epithelial Growth Factor (EGF), TGF-α, TGF-ß and Fibroblast Growth 
Factor (FGF) which can be helpful in wound healing and tissue repairing. 
   In conclusion, saliva is an accessible biofluid that contains components derived 
from the mucosal surfaces, gingival crevices and tooth surfaces of the mouth. Saliva 
also contains microorganisms that colonize the mouth and other exogenous 
substances. For all these reasons, it can potentially provide an insight into the 
relationship between the host and the environment. 
 
1.4 SALIVARY COLLECTION 
Collecting homogeneous samples of saliva is very difficult because standardized 
protocols are lacking. What we know for certain about saliva is its constant variabilty 
due to circadian rhythms during the day. 
There are some independent variables which influence the salivary flow rate and 
which cannot be under control during collection: sex, age, body weight, salivary 
glands dimension, physical and mental health, drugs intake. On the contrary, what 
a dental clinician can do to perform a collecting procedure as accurately as possible, 
 17 
 
is to control dependent variables, like previous stimulation, time, exposition to light, 
body position, temperature. As long as the dental clinician creates homogeneous 
environmental conditions and removes the influence of dependent variables, he will 
be able to perform a useful examination of the salivary fluid [13]. 
- The most important variable to take into account is the time of day 
at which the sample is collected. Best conditions are reported at 
morning fasting or between 8.00 and 11.00 a.m. [14]. Patients should 
avoid eating or drinking during 90 minutes before examination. Once 
the time for collection has been established, it must remain the same 
to compare results from different tests. 
- Time for collection should be appropriate, for example 15 minutes. 
- Patient’s head must be bent forward and maintained in the same 
position. 
- Light and room temperature should be as costant as possible. 
 
There are several procedures which are described in the international literature for 
salivary collection. 
To obtain an appropriate sample of unstimulated saliva there are two main 
techniques: 
- The spitting method: the patient’s head is bent forward and he/she 
sits on the dental chair. He/she should spit the salivary content in 
his/her mouth every minute for at least 5-15 minutes. 
- The drooling method: patient does not spit but lets his/her saliva 
drain constantly in a funnel or test tube. 
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A)                     B)     
Fig.3a: the spitting method; 3b: the drooling method 
(from Sreebny LM and Vissink A [15]) 
On the contrary, if the clinician needs to examine stimulated saliva, there are 
several methods to obtain a correct stimulation of the fluid. 
- The chewing technique: patients chew a piece of paraffin wax for 5 
minutes and then spit the entire content in a dedicated container. 
- The taste technique: some drops of citric acid 2% solution are applied 
in the patient’s mouth stimulating thus the production of saliva from 
the parotyd gland. 
- The absorbent technique: a cotton roll or a sponge gauze is placed 
into the patient’s mouth to passively absorb the fluid stimulated by 
the presence of a foreign body in the oral cavity 
 
These techniques are valid to obtain a collection of the entire mixed saliva which is 
present in the oral cavity, but they do not distinguish from one type of saliva 
produced by a gland or by another [15]. 
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Some authors have tried to introduce more techniques to collect specific saliva from 
a single gland and some ideas have been tested, like for example the Lashley cup 
for the parotyd gland, or the Wolff’s device for submandibular and sublingual glands 
[16]. However, these devices have not encountered much success due to their high 
cost. 
 
A)  
B)   
                  C)    
Fig.4a: Lashley’s cup in position on the Stensens duct’s outlet; 3b-c: Wolff’s device 
for saliva collection (from Sreebny LM and Vissink A [15]) 
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1.5 THE CREVICULAR FLUID 
The crevicular fluid, also known as gingival liquid, is a fluid which is contained in 
the gingival crevice, a space located around a tooth between the wall of the 
unattached gum tissue and the enamel and/or cementum of the tooth. At the base 
of the gingival sulcus there is the junctional epithelium which adhers to the dental 
surface. 
Gingival crevice fluid flow is a decisive factor in the ecology of the periodontal 
pocket or sulcus. It creates a flushing action and an isolation effect. 
- Flushing action: substances put into the periodontal pocket are 
rapidly washed out. Even before the importance of this liquid was 
discovered, clearance of carbon particles and of amalgam particles 
from the gingival sulcus had been reported. 
- Isolation effect: substances from the outside do not easily penetrate 
the periodontal pocket. The crevicular fluid is isolated from saliva and 
this can be demonstrated by the fact that α-amylase, which is highly 
expressed in saliva, is not identifiable in the crevicular fluid. On the 
contrary, the immunoglobulin IgG concentration in the crevicular 
fluid is approximately 100 times that found in saliva [17]. 
 
To obtain a useful collection of crevicular fluid, the clinician should stimulate its 
production mechanically or chemically and then collect samples with a paper cone 
which gets soaked by capillarity. 
 
 21 
 
 
Fig.5: a paper cone is inserted into the crevice for at least 30 seconds to get 
soaked in crevicular fluid.  
 
It has been calculated that during the day a total amount of 0,5-2,5 ml is produced, 
being this production greater in molar areas than in incisive areas. 
The composition of crevicular fluid is similar to that of the insterstitial fluid. It may 
also contain epithelial exfoliated cells and white blood cells, mostly neutrophils. In 
case of inflammation, like during gingivitis or periodontitis, the white blood cells 
amount increases vertiginously. 
Measuring the composition of electrolytes in crevicular fluid is more difficult than 
in saliva due to its very low volume; however, it contains a higher concentration of 
sodium and potassium than that recorded in plasma. 
Different enzymes can be detected inside the liquid, like alkaline phosphatase,                     
ß-glucuronidase, lysozyme and several proteases. 
The main role of crevicular fluid is to protect healthy gingiva, but in case of 
inflammation it becomes a reservoir of dangerous and toxic substances for gingival 
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tissues. Likewise, an excess in calcium levels may lead to the formation of dental 
plaque and tartar. 
Therefore the crevicular fluid analysis is important to detect periodontal pathogens 
or to measure genetic indices when a chronic inflammatory disease is present. 
 
1.6 SALIVA AND CREVICULAR FLUID AS DIAGNOSTIC TOOLS 
Unstimulated whole-mouth saliva is preferred as a biomarker fluid because the 
potential variation created by using different types and intensities of reflex 
stimulation is avoided. One of the drawbacks of using unstimulated whole-mouth 
saliva is that the volume of fluid obtained can be low, particularly in older subjects 
and in those taking xerogenic medications [18]. A broad range of components are 
present in saliva and represent potential biomarkers for different pathological 
entities. 
- Diabetes is a metabolic disease caused by insufficient insulin 
secretion or by insuline resistance, which leads to a glucose 
metabolism disorder. A positive correlation was found between α2-
macroglobulin and HbA1c. Registered levels of α2-macroglobulin in 
saliva could reflect the glycemic control in patients with type 2 
diabetes mellitus. 
- Cardiovascular disease (CVD) is related to the circulatory system and 
includes atherosclerosis, myocardial infarction and coronary heart 
disease. Some authors found that levels of salivary inflammatory 
cytokines, including IL-1ß, IL-6, TNF-α and prostaglandin E2, 
increased significantly in both atherosclerosis and periodontal 
disease. These cytokines might be potential biomarkers for the 
diagnosis of periodontal disease and atherosclerosis. 
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- Pancreatic cancer: it was found that KRAS, MBD3L2, ACRV1 and 
DPM1 levels enabled the differentiation between patients with 
pancreatitis and healthy individuals. There is also a correlation 
between periodontitis and pancreatic cancer onset. Patients with 
periodontitis show a 64% higher risk of pancreatic cancer. 
- Breast cancer: the levels of CA15-3 and c-erb.2 were found to be 
increased in the saliva of patients affected by this cancer. 
- Lung cancer: EGFR mutations in the saliva of patients with non-small 
cell lung carcinoma (NSCLC) have been described. 
- Prostate cancer: miR21 and miR-141 biomarkers can be detected in 
the saliva of patients affected by this tumour. 
- Diagnostic tests for viral infections currently rely on salivary 
biomarkers, such as viral DNA and RNA, antigens and antibodies.  
Hepatitis A virus, hepatitis B virus, hepatitis C virus, HIV-1, measles 
virus, rubella virus and mumps virus could be detected thanks to 
proteomics.  
- Helicobacter pylori: Helicobacter pylori is a widespread bacterium, 
which is found within the water and in some animals’ biological fluids, 
and it is responsible for chronic gastritis and other gastric diseases. 
Apart from the stomach, HP has also been found in the distal 
oesophagus, proximal duodenum, colonic contents, and oral cavity, 
including tonsils and adenoid tissue. 
 
Extensive research on the relationship between the oral cavity and gastric HP 
infection has been published, with numerous studies providing evidence that the 
oral cavity may be a potential reservoir for HP [19]. 
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The third study presented in this dissertation, “Helicobacter pylori in periodontal 
pockets and saliva: a possible role in gastric infection relapses? A preliminary 
study in Northern Italy”, tries to establish whether the presence of HP within oral 
tissues can be an extra-gastric reservoir which contributes to gastric relapses after 
eradication therapy in a determining manner. 
 
A particular subject, which has recently drawn attention in the international 
literature, is the relationship between salivary, crevicular fluid biomarkers and 
Periodontal Disease [20]. 
Periodontal Disease (PD) is a time consuming and expensive condition to treat and 
therefore prevention and early detection are considered important factors by 
dental clinicians. 
Research is trying to develop biomarkers to early detect periodontal disease and 
identify its progression, because current diagnostic approaches do not show the 
disease activity but only assess the clinical evolution of tissue destruction. 
Furthermore, studies of the salivary mediators associated with the disease may help 
in the development of novel therapies aimed at controlling cytokines availability or 
by targeting the intracellular signaling pathways they activate, approaches which 
have proved successful in the treatment of other chronic inflammatory diseases, 
such as Rheumatoid Arthritis. 
 
The fourth study reported in this dissertation, entitled “Rheumatoid Arthritis 
therapies and Periodontal disease: any correlation?”, proposes evaluating the 
correlation between genetic and microbiological markers detected in the crevicular 
fluid in a group of 35 patients affected by Rheumatoid Arthtritis with those collected 
from their bloodstream indicating the rheumatic disease activity. 
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Among the most recognized cytokines which may have a role in periodontal 
inflammatory disease there are Interleukin-1 (IL-1), Tumor Necrosis Factor–α (TNF-
α), Interleukin-6 (IL-6) and Interleukin-10. 
- IL-1 family is produced by a wide variety of cell types and performs 
critical functions in innate and adaptive immune responses to 
infection. IL-1 is a proinflammatory cytokine. In periodontitis, IL-1ß is 
associated with neutrophils recruitment and activation of 
osteoclasts. Furthermore, the association between periodontitis and 
elevated IL-1ß in gingival crevicular fluid is well established. 
- TNF-α has a role in cell proliferation, apoptosis and morphogenesis, 
as well as in host immune defense. It is considered as a key 
proinflammatory cytokine, but it also has numerous homeostatic 
functions in human physiology, including a role in neurological 
regulation. This cytokine is mainly produced by macrophages as a 
primary response to toll-like receptor activation, by T-cells and NK 
cells. The long-lasting success of anti-TNF-α therapy in Rheumatoid 
Arthritis has highlighted how this cytokine is important in 
inflammatory diseases, including periodontitis. 
- IL-6 is produced by innate immune cells as macrophages and 
dendritic cells, but also by some CD4+ T-cells, as well as by 
nonimmune cells, like fibroblasts and endothelial cells. IL-6 is 
increased in many inflammatory diseases and activates B-
lymphocytes. It is interesting that some reports showed how IL-6 
blockade proved to be efficacious in the treatment of Rheumatoid 
Arthritis. Also, whereas some studies have shown that salivary IL-6 
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concentrations are significantly higher in patients with periodontitis 
than in healthy individuals, other have found no differences. 
- IL-10 is widely produced by innate and adaptive immune cells alike 
and is a key anti-inflammatory cytokine, involved in inhibiting and 
regulating proinflammatory immune responses and in promoting 
resolution of inflammation. Thus IL-10 is considered an anti-
inflammatory cytokine, in opposition to IL-6 and TNF-α. 
 
The advantages of saliva as a diagnostic fluid are that it is simple to collect, 
convenient to store, essentially non-invasive and contains high-quality DNA. Saliva 
could become a perfect substitute for blood and research in proteomics may have 
an important role in identifying biomarkers of diseases and potential targets for 
drugs. Besides, it would be possible to diagnose diseases at their early stages.  
However, research on saliva and its applications for the diagnosis of diseases is still 
at the beginning and progress is limited by the lack of standardized methods and 
protocols. 
In this dissertation four experimental studies conducted between 2014 and 2016 
have been described. Each of them analyzed a particular feature of oral fluids and 
verified whether saliva and/or the crevicular fluid may be helpful in diagnosing 
underlying pathologies, monitorizing systemic diseases activity or contributing to a 
better understanding of some idiopathic oral pathologies. 
- In the first study, saliva was quantitatively analyzed through the 
spitting method in a group of 111 patients. Among them, 44 were 
affected by the most common idiopathic psychosomatic disorder of 
the oral cavity, known as Burning Mouth Syndrome (BMS), a 
frustrating condition in which patients refer a burning, tingling, 
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itching chronic sensation in their tongue or oral mucosa in total 
absence of clinical and laboratory findings. Through the use of the 
spitting method, a quantitative analysis of basal salivary flow and 
stimulated salivary flow was performed and interesting findings were 
found in the BMS group compared to other patients. Actually, 
patients affected by the syndrome showed a decreased basal salivary 
flow while the stimulated flow was normal when compared to the 
other groups. This study showed how saliva is a complex fluid, 
composed of different elements coming from each one of the salivary 
glands, and that the central nervous system and emotional attitudes 
are very strong influencing agents on the oral health. 
 
- In the second study, a total number of 35 patients were recruited and 
salivary fluid and crevicular fluid samples were collected to measure 
the presence of Human ß2-defensin, an antimicrobial peptide 
involved in defensive functions but also in immunomodulatory ones. 
A group of 17 patients were affected by the most common 
autoimmune disease of the oral cavity, Oral Lichen Planus (OLP). Data 
collected from this group were compared to other 18 patients, 9 
affected by BMS and 9 as a control group (CTRL). It was observed that 
HBD-2 was strictly linked to the degree of local inflammation and that 
it could become a very important index to measure the disease’s 
activity and its evolution in the future. 
 
- In the third study a total group of 30 patients with a positive diagnosis 
for Helicobacter pylori gastric infection were analyzed with 
microbiological examination performed on salivary and crevicular 
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fluid samples. The aim of this research was to establish whether the 
oral cavity may represent a possible reservoir for gastric infection 
relapses after eradication therapy. Data collected were compared 
with other 30 patients who were negative on gastric examination. 
This study demonstrated that periodontal pockets and saliva contain 
Helicobacter pylori and that it does not depend on a retrograde path 
from the stomach to the oral cavity, but relies on oral health and 
mostly on periodontal conditions, leading thus to claim that oral 
hygiene is useful in preventing the formation of a reservoir of 
microorganisms involved in gastritis and gastric cancer. 
 
- In the fourth study, a total group of 34 patients affected by 
Rheumatoid Arthritis were examined both by the rheumatologist, 
who registered serum values indicating disease activity, and by the 
dental clinician, who described periodontal conditions and collected 
gingival liquid samples. Oral fluids were then analyzed both 
microbiologically and genetically. Several links between rheumatic 
factors and periodontal indices were found. Furthermore, patients 
were divided into groups based upon the drug regimen adopted to 
treat Rheumatoid Arthritis. Patients undergoing treatment with 
metothrexate showed worse periodontal indeces, confirming that 
periodontal tissues and oral fluids represent reliable biomarkers in 
establishing a correlation with systemic diseases. 
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In the end, a total number of 240 patients were recruited in this experimental work 
and each study contributed to new topics in the research on saliva and crevicular 
fluid as potential diagnostic tools for oral pathologies and systemic diseases. 
 
 
Plot 1: histogram showing the distribution of the recruited 240 patients among the 
four studies which are discussed in the dissertation. 
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2.   1st STUDY: LOW BASAL SALIVARY FLOW AND BURNING    
MOUTH SYNDROME: NEW EVIDENCE IN THIS ENIGMATIC 
PATHOLOGY 
 
       2.1 BACKGROUND 
 
2.1.1 Definition 
For at least one century, many researchers have reported in their scientific studies 
and clinical trials a particular symptomatology: oral burning. In the last decades, 
they have sought to elucidate the aetiology, the pathogenetic hypothesis of oral 
burning with clinical research, more or less complete and documented. They have 
identified specific causal factors, local and systemic, able to explain the burning 
sensation and the oral pain [21].  
However, in many patients it has not been possible to pinpoint a specific aetiology 
because of negative results on clinical examination. These clinical findings have 
raised obvious questions, often followed by not very well documented and 
comprehensive responses. A series of terms and definitions has been suggested to 
the scientific arena. A definition that sums up, synthesizes and anticipates a complex 
clinical picture of BMS was expressed by Van der Waal: “The Burning Mouth 
Syndrome (BMS) is an enigmatous condition for both the patient and the clinician” 
[22]. 
The terms glossodynia or glossalgia can be used to describe a painful tongue, and 
the term glossopyrosis to describe only a lingual burning sensation. 
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When little discomfort is experienced, the term lingual dysesthesia can be used. 
Likewise, for complaints elsewhere in the oral cavity, outside the tongue, the terms 
stomatodynia, stomatopyrosis and oral dysesthesia could be used respectively. 
Lamb and Lamey in 1988 [23] defined BMS as a distinct clinical entity of 
multifactorial aetiology, in which no oral mucosa abnormality is evident on clinical 
examination. Any area of the oral mucosa can be affected, but the tongue and 
denture bearing areas are most commonly involved. Besides, van der Waal in 1990 
specified that the term BMS should be used only in patients with idiopathic 
complaints, among which the main symptom is usually described as a burning, 
painful or itching sensation. It is located in the oral mucosa, with or without 
involvement of the tongue and with or without associated symptoms in the oral 
cavity or elsewhere in the body [22]. 
It is well recognized that many patients complaining of a burning mouth also suffer 
from a dry mouth, xerostomia, with or without an associated loss of taste or a 
distorsion of the sense of taste, and with or without a number of other symptoms 
justifying the term of the syndrome. 
Zaskin and Moulton believed that BMS involved a strong emotional component, and 
attributed its cause to psychogenic or psychological factors and psychopathologic 
components. In fact, psychological causes are frequently postulated when no 
physical cause is apparent [24]. 
Some authors classify BMS under the heading of Atypical Facial Pain (ATP). AFP, 
atypical odontalgia and oral dysesthesia, including BMS, may occur either 
sequentially or simultaneously in the same patient, and may be associated with 
facial arthromyalgia in which the temporomandibular joint or its musculature are 
involved [25]. 
In most patients clinical examination is normal and no causative factors are found 
out. Moreover, the International Association for the Study of Pain (IASP) defines it 
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as a pain of at least 4-6 months duration. In 2004 IASP and IHS (International 
Headache Society) defined BMS as a distinctive nosological entity, including all 
forms of burning or stinging sensation in the mouth, pain, associated with an oral 
mucosa that appears normal in absence of local, dental or systemic conditions [26]. 
 
2.1.2 Epidemiology 
The true prevalence of BMS is difficult to establish due to the lack of rigorous 
diagnostic criteria in many of the published series that do not distinguish between 
the symptom of oral burning and the syndrome itself, regarding BMS as only a 
symptom of other diseases. Thus, figures vary widely, with prevalence rangin from 
0,7 to 15% [27]. 
In general, the condition principally affects women, with a ratio of approximately 
3:1. This difference between genders may perhaps be explained by biological, 
psychological and sociocultural factors; however such features have not been 
defined yet. This syndrome is rare in patients under 30 years of age, having never 
been detected in children or adolescents.  Studies into any occupational, 
educational or social grouping are not available. 
Patients are almost exclusively elderly, the mean age of patients being 50-60 years 
(range 36-84 years)[28]. There is a very strong female prevalence greater than 3:1; 
this feature is especially noticeable in patients over 50 years. This could be explained 
by the fact that women seek health care more frequently than men, but it could 
also be suggestive of menopausal factors if the rising prevalence in older women is 
taken into account. 
In recent years a large sample of 123 BMS patients have been visited in Varese 
(Department of Surgical and Morphological Sciences, University of Insubria, ASST 
dei Sette Laghi, Unit of Oral Pathology) and Milano (Department of Biomedical, 
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Surgical and Dental Sciences, University of Milano, Policlinico Hospital IRCCS 
Ca’Granda Foundation, Unit of Oral Pathology and Medicine). Epidemiologic data 
have shown a strong female preponderance with a 4,5:1 ratio to men. The 
registered mean age is 66, ranging between 37 and 90. 
 
 
PATIENTS MEN WOMEN 
123 22 101 
 
Table 1: Sex distribution of 123 BMS 
patients visited during 2014, 2015 and 
2016 
Plot 2: data showed a 4,5:1   female preponderance to men 
 
2.1.3 Aetiology 
It should be considered that an oral burning sensation with the presence of possible 
related presentations can have various origins. Several aetiological causes, local 
and/or systemic, can cause a burning symptom in different oral regions. Local 
factors, identified by dental and periodontal diseases or soft tissue disorders, and 
systemic factors, connected with organic disease, should be considered. 
Among local conditions oral candidiasis, geographic tongue, hairy tongue, fissured 
tongue, median rhomboid glossitis, foliate papillitis, fuso-spirochetal infection, 
inflammatory oral diseases, Oral Lichen Planus, leukoplakia and erythroplakia could 
82% FEMALES VS 18% 
MALES
FEMALES MALES
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be associated with an oral burning complaint. Food allergy, smoke and alcohol 
consumption contribute to oral burning. 
Among odontogenic factors, dental treatment, denture-related problems, 
sensitivity to acrylic resin, galvanism, metal allergy, parafunctional behaviour may 
be related to the onset of an oral burning sensation. 
Among systemic causes, which may be linked to oral burning, hormonal 
disturbances, iron-deficiency anaemia, pernicious anaemia, vitamin B12 and 
nutritional deficiencies, hypocalcaemia, hypo or achlorhydria, diabetes mellitus, 
vascular disturbances, Sjögren’s Syndrome and xerostomia, side-effects of 
medication, hypothyroidism, immunologic disturbances and rheumatism should be 
ruled out. 
If patients report an oral burning sensation and the clinical examination does not 
show any clinical sign, the diagnostic hypothesis will be that of BMS. A final diagnosis 
can only be made after further laboratory tests with negative results. 
 
2.1.4 Clinical features 
BMS includes a wide variety of complaints. The burning pain is always reported. 
Other disorders such as prickling, itching or other bizarre sensations may be 
present. Although patients often describe the burning sensation as being 
intolerable, it is rarely able to impair the patient’s ADLs. A somewhat similar 
experience was reported by Hughes, who described the psychiatric disorders seen 
in 138 consecutive attenders at a psychiatric clinic in a dental hospital. A large 
number of BMS patients was included into that group [29]. 
The symtpoms of BMS almost always have a bilateral pattern and, in contrast to 
symptoms in neurological disorders, have a non-anatomic and non-dermatomeric 
distribution. However, during the clinical exam specific sites of complaints can be 
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identified. The burning sensation most frequently occurs in the distal structures of 
the mouth, a pattern similar to that seen in symmetrical polyneuropathies. Most 
patients with BMS describe the burning sensation as occurring at more than one 
site in the mouth. In several reports the tongue and especially its tip is the most 
common location. 
Almost without exception, the symptoms of BMS ceaselessly persist over a period 
of months or years, without distinct periods of remission. 
The daily pattern of symptoms is constant for each individual patient. For instance, 
in some patients the burning is present day and night. In most patients with BMS, 
the symptoms are not present on waking up but set off and worsen in severity as 
the day progresses, without preventing the patient from falling asleep. 
In 1989, Lamey and Lewis defined three subtypes of oral burning in BMS on the basis 
of diurnal variation of its symptomatology [30]. 
Type 1 is characterized by progressive pain. Patients wake up without pain, which 
then increases throughtout the day and reaches its maximum intensity by early 
evening. Type 1 affects approximately 50% of patients. This type may be associated 
with systemic disorders, like hormonal imbalance in women. 
In type 2 the burning sensations are unvaried and continuous throughout the day 
and patients find it difficult to get to sleep. Type 2 represents 40% of patients. These 
patients usually present with associated psychological disorders and are the most 
resistant to therapy. 
A burning-free period at night is always present in type 1 and type 2. 
In type 3 symptoms are intermittent and characterized by symptom-free days, with 
atypical pain and location. It accounts for 10% of patients. It seems that contact with 
oral allergens and food allergy can play an important aetiologic role in this group. 
Although in terms of aetiology there are similarities between these subtypes, it is 
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important to distinguish between them, since each type requires specific medical 
investigation and have different prognosis.  
Various diagnostic criteria for the classification of BMS have been suggested but 
none of these have been validated [31]. 
The onset of BMS has been related to a previous dental procedure in 33% of subjects 
[32].  Other patients relate the onset of the syndrome to family health problems, 
threatened loss of a loved one, move and adverse life events. Other associate the 
symptoms with menopause, retirement, depression or multiple somatic complaints. 
Data from the international literature indicate that although BMS patients are 
affected by elevated psychological stress, the onset of BMS symptoms is not 
necessarily correlated with stressful life events. 
A number of other oral complaints have been reported in BMS patients. Taste and 
sometimes olfaction disorders are often described, while xerostomia is among the 
most commonly reported associated symptom, being noted in more than 60% of 
patients. 
Systemic symptoms often associated with BMS are gastrointestinal disorders, like 
constipation, heartburn, nausea, vomiting and colitis. 
Headache, migraine, neck/back ache, skin disorders, dysfunctional uterine bleeding 
have been recorded in some papers [25]. 
 
 
2.1.5  Diagnostic management 
When a brief history of the nature and duration of symptoms and an inspection of 
the oral cavity do not clearly reveal the cause of BMS, a more detailed approach is 
necessary.  
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Firstly, it is important to collect a detailed description of symptoms, such as their 
nature, location and distribution, their progress during the day, any possible 
interference with the individual’s daylife. 
Secondly, the clinician shoud collect data about the patient’s medical history and 
any previous consultation with other physicians. It is essential to check for 
hypertension and metabolic diseases. Especially in patients who also complain of 
xerostomia, taking an accurate drug history is mandatory. 
At any rate, regardless of the nature and exact distribution of symptoms, a thorough 
inspection of the entire oral cavity, including the tongue, should be carried out 
under the appropriate conditions. A localized burning or itching sensation can be 
the first sign of a malignant or premalignant mucosal lesion. Ignoring the 
importance of such symptoms or overlooking minor but ominous mucosal changes 
may have dramatic sequelae. It is striking that in most patients whose complaints 
include xerostomia a normal or sometimes even an abundant flow of saliva is found 
on inspection. The result of the oral examination can be more or less decisive for 
the future management of the patient.  
When no oral mucosal lesions are detected on ispection, a large number of issues 
and questions need to be focused on. Cytologic or histologic examination of the 
mucosa at the site of burning or any other oral site does not contribute in any way 
to the further management of the patient. Even the collection of samples for oral 
smear tests is not helpful. 
At this stage the patient needs detailed information about his/her problem. If 
possible, the spouse or any other close relative, should be present during any 
further interview with the patient. Any information about the syndrome should be 
factual and detailed. 
1. BMS is a rather uncommon, but definitely not exceptional, syndrome 
that affects menopausal and post-menopausal women much more 
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often than men. Not many doctors and dentists are familiar with the 
signs and symptoms of the syndrome, which accounts for the possible 
different advice the patient may have received in the past. 
2. In many cases aetiology is unknown, which results in a wide range of 
beliefs held by the patient, including the fear of an underlying 
malignant disease. By explicitly mentioning the unlikelihood of the 
latter, a number of patients will be completely reassured and will not 
require any further treatment or follow-up. 
3. Another widely often-held belief by the patient is a possible allergy 
to food, toothpaste, chewing gum etc., which is rarely if ever the 
cause of BMS complaints. The same holds true for smoking habits and 
alcohol consumption. 
4. As in other ailments or diseases for which no distinct cause can be 
found, the possibility of an underlying psychogenic cause is 
sometimes brought up. Nevertheless long lasting and intensive 
symptoms are more likely to affect someone’s psychological status 
rather than vice versa. A certain amount of caution is advisable at this 
point, and a referral to a psychologist is to be taken into account. 
 
 After the anamnestic procedure and oral examination, it is imperative to rule out 
any underlying systemic disease which could be associated with oral burning. Blood 
chemistry and allergological tests should be performed to demonstrate that the oral 
complaint is an idiopathic burning pain. 
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2.1.6 Therapy 
BMS patients very often report a previous visit to other specialists, such as the 
general practitioner, who often does not know what BMS is, the gastroenterologist, 
who focuses his/her attention on gastro-esophageal reflux disease, the 
psychologist, who only considers the psychosomatic aspects of the syndrome or the 
general dentist, who is afraid that burning symptoms flare up after a dental surgical 
procedure or other kinds of treatment. 
This confusion among different specialists becomes a frustrating condition for 
patients, who receive completely different answers and feel misunterstood. 
Consequently, a point of reference should be found, and this could be provided by 
the stomatologist. 
The stomatologist is actually the only specialist able to visit these patients, and 
he/she should be the coordinator of a team work also involving other consultants 
such as the neurologist, the rheumatologist, the gastroenterologist and the 
endocrinologist, according to the different needs of each patient. 
In the international literature, different therapeutic protocols have been reported. 
Acupuncture, antihistaminics, inhibitors of gastric acid secretion, multivitamin 
integrators, antidepressants, antipshycotics (i.e. quetamine), even 
electroconvulsive therapy have been recommended [33]. 
As a result, it is imperative to establish a therapeutic protocol which could help the 
clinician to relieve the burning sensation. 
Firstly, topical antifungal therapy can be prescribed.  
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The topical antifungal therapy is used to clean up the oral cavity from Candida 
albicans and to exclude the possibility of a burning sensation due to the presence 
of a subclinic oral candidiasis. 
After this first step, the use of salivary substitutes, in the form of mouth rinses to 
effectuate at least 3 or 4 times a day for a long period, is prescribed. 
Salivary substitutes are very important because they restore the natural equilibrium 
among the different components of oral fluids and help protect and lubricate oral 
mucosa. 
For example, they contain lactoferrin, an enzyme which performs a bacteriostatic, 
antymicotic and antiviral function, making iron unavailable to microbes which 
require it as a necessary metabolite for their cycle. 
Salivary substitutes also contain an important agent, lyzozyme, which is effective in 
the natural defenses against microbes. 
Lactoperoxidase is an important enzyme which catalyzes the oxidation of 
thiocyanate. The products of this oxidation serve a powerful bactericidal function. 
Finally, the salivary substitutes contain whey proteins, which are fundamental to 
restoring oral cavity’s omeosthatis. 
The following therapeutic step is represented by the use of specific substances 
which can desensitize the small nerve fibers associated with oral burning. 
At the end of the nineties Nature published an interesting paper which 
demonstrated the existence of specific receptors for capsaicin, the molecular 
principle contained inside red hot peppers and responsible for the characteristic 
burning sensation in the oral cavity felt after their ingestion [34]. 
This paper paved the way for further research and the discovery of a family of 
particular receptors: the Transient Receptor Potential Vanilloid (TRPV). 
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This is a family of transient receptor potential ion channels. These channels are 
selective for calcium and magnesium over sodium ions. 
The most interesting feature of these vanilloid receptors is that they can be 
activated at a different thermal threshold, while specific stimulation with chemical 
substances is converted into thermal sensation, i.e. a burning sensation after the 
assumption of capsaicin contained in the red hot pepper or a cold sensation after 
eating a gum or a sweet containing piper mint. 
TRPV-1 was the first vanilloid receptor to be discovered and it has been studied 
because of its specific responsiveness to capsaicin. 
Capsaicin is produced by chilly peppers and gives a sensation of burning in any tissue 
with which it comes into contact. Probably it is produced by red hot peppers as 
deterrent to certain mammals. 
The most interesting clinical feature is that upon prolonged exposure to capsaicin, 
TRPV-1 activity decreases, a phenomenon called desensitization. This process 
involves intracellular calcium and specific signaling pathways. 
Desensitization of TRPV-1 is thought to underlie the paradoxal analgesic effect of 
capsaicin. 
The process of desensitization of TRPV-1 receptors could be obtained through the 
use of topical capsaicin, thanks to the successful outcome achieved by the 
treatment of diabetic peripheral neuropathy reported in the literature [35]. 
The prescription should include red hot chilly pepper powder mouth rinses 3 times 
a day. Patients should collect just the tip of a coffee spoon of red hot pepper powder 
and stir it in half a glass of water. It corresponds approximately to a concentration 
of 3,54 micrograms/ml of capsaicin [36]. 
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After a mouth rinse of about 30 seconds patients should spit and must not take any 
food or drink in their mouth for at least 30 minutes. 
 
The results of 99 patients who underwent treatment with topical capsaicin in Varese 
e Milano confirmed the importance of topical capsaicin.  
Patients were subdivided into two groups, cooperative and non-cooperative, by 
using the psychological multidimension scale questionnaires, like HAM-A, HAM-D 
and Mc Gill-Pain Questionnaire. 
After 1 month the percentage of success was 67, but there was a significant 
difference between the two groups: 74% of success among cooperative patients, 
but only 44% of success among non-cooperative patients. 
After 3 months, 6 months and 1 year the percentages of success stayed unchanged. 
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Table 2a and Plot 3a): percentages of success and unsuccess after 1 month of 
treatment with topical capsaicin followed by a subdivision into the two groups of 
patients (collaborative vs non-collaborative) based on the results of psychometric 
questionnaires; Tables and Plots 3b-c-d): percentages of success and unsuccess 
after 3, 6 and 12 months respectively. 
   
Treatment was regarded as successful if it led to a decrease in oral burning and 
lasted over time. 
Topical capsaicin is very effective in the treatment of burning symptoms in BMS 
patients, but it is succesful in those patients whose complaint seems to have a 
neuropathic origin, whereas those patients whose condition is likely to be linked to 
psychogenic factors do not obtain a satisfactory percentage of success. 
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Another promising therapeutic approach which could be used together with topical 
capsaicin is Low-Level Laser Therapy (LLLT), also known as Biostimulation. 
LLLT acts significantly on NADH reduction and cellular respiration, increasing thus 
energy levels and producing an antalgic effect. 
Moreover, it contributes to activate the serotoninergic inhibitory descending 
pathway. 
Several studies described a positive effect of LLLT in the treatment of burning mouth 
symptoms [37]. 
If topical therapies do not work as aspected, or if the clinician wants to improve the 
therapeutic effectiveness, he/she may prescribe alpha-lipoic acid (ALA). 
ALA is a neuroprotector and helps the trophism and metabolism of nerve fibers. In 
past years, it was thought of as the therapy of first choice, but now its efficacy has 
been re-evaluated and it is only prescribable as an adjuvant drug [38]. 
The percentage of success in the analyzed patients is nearby 20%. 
Alpha-lipoic acid is prescribed in the dosage of 400 mg per day for the first 10 days 
and then 800 mg per day for the next 30 days. 
If previous therapies do not bring about any substantial improvement in oral 
complaints after topical applications, the stomatologist should refer patients to the 
neurologist who will prescribe anticonvulsant drugs (i.e. Gabapentin tablets or Pre-
gabalin capsules). 
The last chance lies in psychiatric drugs, like benzodiazepines (i.e. Clonazepam) or 
SSRI (Fluoxetine or Sertraline). 
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The international literature has recently suggested the use of Duloxetine as the 
most effective SSRI in the treatment of Burning Mouth Syndrome [39]. 
The problem is that very often patients visit a dental clinic with an already positive 
pharmacological anamnesis for these drugs, and it becomes very difficult to manage 
a change in their therapy or find a solution to their problems. 
 
In short, a correct diagnosis, which consists in the exclusion of all those local or 
systemic conditions possibly related to oral burning is the mainstay of any future 
treatment. 
Afterwards, it is fundamental to establish a strict and thorough therapeutic protocol 
following a “staircase approach” from the peripheral nerve fibers to the central 
nervous system. 
But both diagnosis and therapy require a psychological approach to BMS patients. 
Specific questionnaires should be administered to distinguish between 
predominant neuropathic BMS and predominant psychogenic BMS. 
If the clinician is faced with neuropathic BMS, he/she could prescribe topical 
therapies: antifungal therapy, salivary substitutes, topical capsaicin and LLLT and 
alpha-lipoic acid; in 75% of cases he/she can treat his/her patients with topical 
therapies without referring them to a neurologist. 
On the contrary, if he/she has to deal with psychogenic BMS, 80% of patients will 
require a neurological consultation, and only a few patients will notice a slight 
improvement with topical therapies. Moreover, topical therapies could even 
worsen patients’ conditions over time, since the situation may become frustrating 
both for them and the clinician. 
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So, when a psychogenic BMS is evident, it is highly advisable to refer patients to the 
neurologist immediately, so as to establish a systemic therapy. 
 
2.1.7 Update on the origin of the syndrome 
The pathophysiology of primary BMS is a conundrum and has caused a big 
controversy over the years. The aetio-pathogenesis seems to be complex and in a 
large number of patients probably involves interactions among local, systemic 
and/or psychogenic factors. Particular emphasis has been placed on the concurrent 
symptoms of dry mouth and taste alterations [40]. 
The role of the peripheral nervous system, particularly pertaining to concurrent 
dysgeusia has been a topic of study. The results in the international literature 
suggest that BMS oral burning may be a disorder of peripheral pain pathways, 
accompanied by a variety of positive and negative neurological findings in some 
patients. Ito et al [41] in 2002 demonstrated in a case-control study that the thermal 
pain threshold on the tongue and the duration and intricacy of the pain complaint 
was significantly higher in BMS patients than controls, suggesting a relationship 
between the pain and peripheral nerve dysfunction at the tongue and/or central 
dysfunction in patients with BMS. 
Interesting links have recently emerged between BMS and peripheral nerve 
damage. Lauria and co-workers showed that BMS patients had a significantly lower 
density of epithelial nerve fibers in the biopsy specimens of the anterior two thirds 
of the tongue than controls. This feature was more evident with a longer duration 
of symptoms. Epithelial and sub-papillary nerve fibers showed diffuse 
morphological changes indicating axonal degeneration [42]. 
A similar experiment is being conducted in Varese, analyzing samples from 8 
patients with primary BMS and comparing them with negative controls. 4 of these 
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patients underwent topical therapy with capsaicin for one month before biopsy, 
while the other 4 patients started therapy after the procedure. The two subgroups 
show differences at confocal microscopy examination. 
 
 
Fig. 6 and Plot 3: biopsy specimens collected from patients affected by BMS. Each 
sample was processed and stained with Hematoxylin-Eosin, Silver stain and 
analyzed at confocal microscopy with direct immunfluorescence to detect anti-
TRPV1 antibodies directed against receptors for capsaicin. Images A-B-C show the 
results from a patient who underwent biopsy before starting topical therapy with 
capsaicin. Images from D-E-F show the results from a patient who underwent biopsy 
after one month of topical therapy with capsaicin. The plot shows a dycotomic 
distributions of TRPV-1 signal expressed by the two groups. 
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Evidence for chorda tympani hypofunction in BMS has recently been presented [43]. 
Furthermore, an abnormality in the blink reflex has been recorded [44]. Based upon 
clinical and histopathologic findings, BMS could be regarded as a chronic, slow and 
burning pain with a neuropathic origin not well explained. 
In addition to changes at the peripheral level, data emerge that illustrate the 
involvement of the central nervous system and the interaction with the peripheral 
nervous system [45]. Recent data from animal experiments suggest an important 
role played by the basal ganglia in the processing and sensorimotor rating of 
nocipeptive information. PET scans revealed in some BMS patients that the 
presynaptic dopaminergic function in brain was significantly decreased in the right 
putamen compared to control subjects. The finding of decreased striatal FDOPA 
untake in the putamen supports the involvement of the nigrostriatal dopaminergic 
system in pain. Other studies indicated that thermal stimulation in BMS patients 
was associated with increased cerebral blood flow as observed in functional 
Magnetic Resonance Imaging [46]. 
The additional finding that estrogens function as neuroprotectants of the 
nigrostriatal dopaminergic system and decline with menopause, could help to 
explain the age and gender predilection of this disorder. 
Already in 1920 a possible psychogenic cause of BMS was mentioned by Engman, 
but even in the most recent literature much attention has been paid to possible 
psychogenic causes. 
Patients with resistant BMS are significantly more easily fatigued and sensitive and 
tend to be more concerned about their health. With regard to psychologic 
functioning, BMS patients have much more difficulty taking the initiative, become 
dizzy more easily and have more sad thoughts. They also complaint of palpitations 
and/or precordial pain more often. The observed significant differences in 
personality and psychologic functioning might suggest that burning sensations are 
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psychosomatic symptoms in these patients [47].  Approximately 21% of BMS 
patients studied in the literature have psychometric data that show a likelihood of 
psychologic distress, and further evaluation by an appropriate health professional 
should be recommended for such individuals. 
The role of saliva and local environmental factors have been investigated, including 
salivary gland dysfunction and altered mucosal blood flow [48]. 
Some authors deduced that mucosal atrophy may result from altered salivary ionic 
composition and may be accompanied by a peripheral oral neuropathy originating 
from dysfunction [49]. 
 
      2.2    AIM 
The current study proposes that the basal and stimulated salivary flows in a group 
of patients with BMS be measured and the outcomes compared with the results of 
a control group (CTRL) and a group of patients with Oral Lichen Planus (OLP), the 
most common chronic inflammatory autoimmune disease of the oral cavity. The 
aim is to check whether there is a quantitative decrease in salivary flow among BMS 
patients to offer a fresh perspective to better understand the contributory effect of 
saliva in this misdiagnosed pathology. 
 
 
      2.3    MATERIALS AND METHODS 
A group of 44 BMS patients were identified following a thorough diagnostic 
protocol, relying on a diagnosis of exclusion and the application of Scala’s criteria 
for the assessment of BMS [45]: the presence of a burning, scalding, tingling and/or 
numb sensation bilaterally in the mouth for at least 6 months with total absence of 
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clinical and radiographic findings; the contemporaneous presence of secondary 
symptoms such as xerostomia and/or dysgeusia; the exclusion of oral pathologies 
or local irritating factors; negative haematochemical analyses to rule out all 
systemic factors linked to oral burning sensations such as vitamin B12 or iron 
deficiency, hepatic enzyme alterations, autoimmune diseases; the exclusion of 
allergy to dental restorative elements by a specific skin patch test series; and 
negative results on cytological and/or microbiological examination. 
A second group of 27 patients affected by OLP was identified on the basis of clinical 
and histological examinations. Among these patients, there was an equal 
distribution of the different subtypes of OLP: papular, reticular, hyperplastic, 
atrophic, erosive and ulcerative. No cases of bullous OLP or lichen planus 
pemphigoides were included in the current study. 
Finally, 40 healthy patients were chosen as a control group (CTRL) with similar 
epidemiologic and demographic distributions to the other two groups. 
This study was included in a more articulated research programme on salivary 
volumes in different pathologies: oral candidiasis, OLP, BMS and several conditions 
such as pregnancy, smoking and drug-related xerostomia. The choice of OLP was 
made because it is the most representative chronic inflammatory pathology 
affecting oral mucosae and to highlight the peculiarity of the outcomes registered 
in the BMS group. 
During the first appointment, an informed consent form was provided to patients, 
followed by a questionnaire to record the participants’ systemic health history and 
their drugs consumption, as well as their dietary habits and any potentially harmful 
habits such as smoking. 
The inclusion criteria were informed consent to the protocol, good compliance, age 
between 40 and 80 years, dental restorations or prostheses in good repair and a 
healthy periodontal condition. Non-cooperative patients, pregnant women and 
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patients with a history of oral radiation were excluded from the protocol. This study 
was approved by the Institutional Review Board for research programmes. In 2015 
it was published on the Journal of Oral pathology and medicine. Authorization for 
the use of the paper in this PhD dissertation is enclosed. 
The basal salivary flow and the stimulated salivary flow in the three groups of 
patients were measured using the “spitting” method, which is a simple and reliable 
method reported in the international literature [15]. The patients were asked to spit 
every minute for 5 min and to avoid swallowing or other confounding factors. The 
examination started after patients had spat all oral fluid secreted in their mouth. 
Subsequently, they were asked to repeat the procedure a second time, but a drop 
of 0,2 ml of citric acid (2%) was placed on their tongues every minute to stimulate 
salivary secretion. The stimulation was begun soon after the patients had spat all 
oral fluid in their mouth. Finally, the amount of citric acid added during the 
procedure (1 ml) was subtracted from the total reported flows. 
After 2 weeks, the patients underwent the same procedure but for 15 min, and the 
basal and stimulate salivary flows were recorded. A total volume of 3 ml of citric 
acid was added during the procedure and was subtracted from the overall quantity 
of stimulated salivary flow. 
The choice of measuring the salivary flows and volumes twice and for different 
times was to verify the homogeneity of the outcomes in each patient and their 
reproducibility during a shorter and a longer stimulation. Furthermore, repeating 
the procedure was important to help patients be at their case with the procedure 
and the operator. 
The procedure was performed by the same operator, in the same place, at the same 
time in the morning to avoid hormonal influences, under the same lighting 
conditions and in absence of potential confounding factors [14]: light’s variations, 
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changing in dental chair position during the examination, noise, speech and 
changing in head’s inclination. 
The distribution of basal and stimulated salivary flow volume (ml) and rate (ml/min) 
in each group was summarized by box plots and histograms, respectively, providing 
mean and total values. 
To test the null hypothesis of no difference in salivary flow volumes among the three 
study groups, a standard analysis of covariance was performed, with age and sex, 
potential confounders, as covariates. The estimated mean flow volume and 
confidence intervals by group were reported, as well as the P-value from the F test 
for overall association (2 degrees of freedom test). The pairwise comparison t-test 
P-values for testing the difference between each pathological group (OLP and BMS) 
vs the control group were reported. All the analyses were done by using the SAS 
software, 9.2 release (SAS Institute Inc., Cary, NC, USA). 
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Fig. 7: The current study was published in the Journal of Oral Pathology and 
Medicine in 2015. 
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Fig. 8: authorization for the use of the published paper in this PhD dissertation. 
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Fig.9: informed consent which was filled in by patients before undergoing salivary 
examination 
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      2.4    RESULTS 
 
A total number of 111 patients were recruited in this study. 44 patients were 
affected by primary BMS, 27 by OLP and 40 were included as healthy. 
The mean age in the BMS group was 67 with a F:M=5,6:1 ratio. 
The mean age in the OLP group was 64 with a F:M=4,4:1 ratio. 
The mean age in the CTRL group was 62 with a F:M=4,8:1 ratio. 
Each group underwent a first examination of the basal and stimulated flows for 5 
min, followed by a second examination after 14 days for 15 min. The outcomes as 
to both the salivary flow rate and the total salivary volume were recorded. 
Subsequently, the mean salivary flow rates and volumes were calculated for both 
the basal and stimulated salivation conditions. 
In the CTRL group, the mean basal flow rate was 0,34 ml/min for the 5-min 
examination and 1,73 ml/min for the 15-min examination.  
The total basal salivary volumes were 1,7 ml during the first test and 5,9 ml during 
the second one, while the total stimulated volumes were 8,5 ml during the 5-min 
examination and 25,9 ml during the 15-min examination. These values 
corresponded with the values reported in the international literature [5]. 
In the OLP group, the mean basal flow rate was 0,36 ml/min for the 5-min 
examination and 0,37 ml/min for the 15-min examination, while the mean 
stimulated flow rate was 1,56 ml/min for the 5-min examination and 1,68 ml/min 
for the 15-min examination. The overall basal salivary volumes were 1,8 ml for the 
first examination and 5,6 ml for the second one, while the total stimulated volumes 
were 7,8 ml during the 5-min examination and 25,3 ml for the 15-min examination. 
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There were no statistically significant differences between the CTRL group and the 
OLP group, with P-values of 0,9 and 0,8 for the basal flow volumes during the 5-min 
and 15-min examinations, respectively, and 0,5 and 0,8 for the stimulated flow 
volume results. 
In the BMS group, the mean basal flow rate was 0,18 ml/min for the 5-min 
examination and 0,19 ml/min for the 15-min examination, while the mean 
stimulated flow rate was 1,78 ml/min for the 5-min examination and 1,73 ml/min 
for the 15-min examination. The total basal salivary volumes were 0,9 ml for the 5-
min examination and 2,9 ml for the 15-min examination, while the total stimulated 
salivary volumes were 8,9 ml during the first test and 26 ml during the second one. 
While there were no statistically significant differences between the three groups 
with regards to the stimulated volumes (overall F test: P=0,6 for the 5-min 
examination and P=0,9 for the 15-min examination; BMS vs CTRL group: P=0,7 for 
the 5-min examination and P=0,9 for the 15-min examination), an important 
significant difference was found for the basal salivary flow among the three groups 
(overall F test: P=0,002 for the 5-min examination and P=0,0002 for the 15-min 
examination). In particular, the salivary rate was half in the BMS if compared with 
the control group (BMS vs CTRL group: P=0,006 for the 5-min examination and 
P=0,003 for the 15-min examination). A graphical representation of the salivary 
volumes is provided as a box plot. 
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Plot 4a): mean flow rates among the three groups. Both the basal and stimulated 
salivary flows of the CTRL group corresponded with the values reported in the 
literature. In the BMS group, a lower basal salivary rate was registered when 
compared with the other two groups, while the stimulated flow rate was equal; 4b): 
salivary outcomes among the three groups. The stimulated flow appeared to be 
equal in the BMS group when compared with the other two groups, while the basal 
salivary flow was very low when compared with the OLP and CTRL groups. 
 
Table 3: mean salivary flow values and following statistical analysis. 
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Plot 5: box-plot charts. Evidence of the decreased level of basal salivary flow in BMS 
patients during both the 5-min (A) and 15-min examination (B). In contrast, the 
stimulated salivary flow of BMS patients at the 5-min (C) and 15-min (D) 
examination appeared to be equal when compared with the other groups. 
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     2.5    DISCUSSION 
Burning Mouth Syndrome is a very enigmatic pathology of unknown 
aetiopathogenesis that is characterized by the presence of a chronic burning 
sensation in the oral mucosa with the absence of related local clinical findings or 
systemic conditions. 
It mainly affects post-menopausal women, and it is associated with secondary 
symptoms such as xerostomia, which is present in more than 60% of patients. 
Many theories have been developed to explain the pathogenesis of this pathology, 
but no one has been enlightening yet. A group of scientific papers has claimed that 
the onset of this syndrome is mainly attributable to psychogenic factors [28], while 
other researchers think BMS is a neuropathic disorder [42]. 
Nevertheless, xerostomia is one of the main symptoms noted by patients, while 
hyposcialia and salivary gland disorders are absent. 
The current study suggests measuring the basal salivatory flow and the stimulated 
salivary flow in BMS patients and comparing these rates with rates from a group of 
OLP patients and a control group. 
The OLP group was not included for its statistical significance per se, since a BMS 
and a CTRL group were sufficient to compare the outcomes. However, OLP is the 
most frequent chronic inflammatory condition of oral mucosae and the normal 
values registered in this group corroborates the peculiarity of the outcomes 
registered in BMS patients. Otherwise, it could be thought that a reduced flow may 
be a consequence of any condition affecting the oral mucosa or the salivary glands, 
and that it is not strongly associated with burning mouth syndrome. The outcomes 
of the research reveal a very low basal salivary flow in BMS patients compared with 
the other two groups, but the stimulated salivary flow is similar, although not 
higher, in BMS patients. 
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This means that salivary function is preserved in burning mouth syndrome. In fact, 
during stimulation, the salivary glands are able to produce the same quantity of 
saliva as in the other two groups. However, a low basal flow was registered during 
the test, which could be a key element to better understand the secondary 
symptom of xerostomia complained of by BMS patients.  
The hypothesis is that chronic assumption of antihypertensive, anxiolytic and 
antidepressant drugs on one side and the concomital presence of psychological 
behaviour distress on the other side could influence the basal tone of those salivary 
glands responsible for the basal flow function, such as the submandibular, 
sublingual and the minor salivary glands. These glands are innervated by 
parasympathetic fibers which refer to the upper salivatory nucleus. On the contrary, 
stimulated flows are produced especially by the parotyd gland, whose innervation 
relies on the function of those parasympathetic fibers which refer to the lower 
salivatory nucleus. In fact, patients usually describe a slight or even a dramatic 
improvement in their oral symptoms while eating or stimulating their salivary 
function with a chewing gum. During the examination, patients did not report a 
marked improvement in oral symptoms, as it often happens when they normally 
eat, but this is probably due to the application of citric acid which can be irritant. 
Further research should be carried out to better investigate this phenomenon 
through the use of more specific salivary tests and functional neurophysiological 
imaging. 
This hypothesis should be verified with more specific salivary volumes collecting 
methods, for example Crittenden cups, as the spitting method of saliva collection is 
admittedly easy to use but is open to criticism due to its non-selective nature. It is 
impossible to distinguish parotyd saliva from submandibular, sublingual and minor 
salivary gland secretions. Whether this phenomenon is one of the aetiological 
factors or only a concomitant one in Burning Mouth Syndrome must be 
investigated. 
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This study does not contribute to our understanding of the pathogenesis of BMS or 
to unifying the neuropathic and the psychogenic theories, but it provides evidence 
and new topics for further investigation to find a solution to the enigma represented 
by the pathogenesis of Burning Mouth Syndrome. 
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3.       2nd STUDY: HUMAN BETA-2-DEFENSIN IN ORAL LICHEN PLANUS AND 
BURNING MOUTH SYNDROME 
 
     3.1   BACKGROUND 
 
 3.1.1 ANTIMICROBIAL PEPTIDES (AMPs) 
All living beings are exposed to the attack from different infective agents, 
such as bacteria, viruses, yeasts, etc. 
The Immune system represents the host defense against these agents, 
distinguishing them from the organism’s own healthy tissue. 
In the human being the defensive response to infective agents is carried out 
by the innate immune system and by the adaptive immune system. 
The innate immune system is primitive, highly non-specific and thus active 
against non-recognized agents; it acts in a generic way eliciting an immediate 
response to infection, but it does not provide long-lasting or protecting 
immunity to the host.  
The innate immune system is an evolutionary ancient defense strategy and 
it is predominant in plants, fungi, insects and primitive organisms. 
Contraversely, the adaptive immune system is highly sophisticated: it 
requires the recruitment of different cell types, the production of antibodies 
and the activation of complement. It is highly specific and retains “memory” 
of the dangerous molecules [50]. 
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This process of acquired immunity is the basis of vaccination. Like the innate 
system, the adaptive system includes both humoral immunity components 
and cell-mediated immunity components, but it is highly specific to a 
particular pathogen and the response is enhanced to subsequent encounters 
with that pathogen. 
The innate immune system’s activity relies on the maintenance of physical 
barriers, which divide tissue from surrounding environment (i.e. cute, 
epithelia), the phagocytic cell lines, the complement pathway and the 
Antimicrobial peptides (AMPs). 
 
 
Fig. 10: the immune system defensive response to infective agents is 
carried out by the innate immune system and by the adaptive immune 
system 
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The Antimicrobial peptides (AMPs) are polypeptides of less than 100 amino 
acids that are found in host defense settings and have antimicrobial activity 
at physiological concentrations under conditions prevailing in the tissues of 
origin [51]. 
They represent an ancient arm of the innate immune system whose role is 
to directly neutralize invading microbes. Over 1500 AMPs have been 
described from different living beings, including plants, birds, insects, 
mammals, humans. 
The first description of the presence of AMPs was in bacteria and fungi. They 
were originally regarded as unique defense molecules in unicellular 
organisms [52]. Some of these molecules seem to be independent from 
ribosomal translation and derived from enzymatic synthesis. In 1962 the field 
of research was extended with the description of the hemolytic bombinin 
peptide from the load Bombina variegata [53]. Even though the initial focus 
was on its hemolytic properties, some authors tried to emphasize its 
antimicrobial properties, but failed [54]. Hence, research in this province 
stopped for almost twenty years. In 1980 the first AMPs, named cecropins, 
were isolated from hemolymph of Hyalophora cecropia [55] and they began 
to provide an explanation of how insects, which do not have the adaptative 
immune system, defend themselves effectively. 
In late 1980s the α-defensins were found in mammaliam cells, including 
human cells, and this led to consider AMPs associated not only with 
organisms lacking in an adaptative immune response. Finally the discovery 
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of AMPs in the African clawed frog Xenopus laevis demonstrated how the 
antimicrobial peptides are widespread among many other species [56]. 
Even though the number of AMPs in nature is large, there are some general 
structure features that are shared among them. They are usually small 
peptides, commonly made up of about 30 amino acids, and are generally 
positive charged. 
They show an amphipathic structure which is crucial for their antimicrobial 
properties: it seems that the positive charged molecules interact with 
negatively-charged phospholipids of microbial membranes, while their 
hydrophobic residues, which are 40-50% on average, aid integration into the 
microbial cell membrane and lead to its disruption [54]. 
First named as AMPs due to their antimicrobial properties, other biological 
effects of AMPs have been described recently: chemotaxis, 
immunomodulating activity, angiogenesis and wound repair. This is the 
reason why the ancestral AMPs represent an interesting and challenging field 
of research [57]. 
In mammals there are many AMPs, but they can be classified into two 
families that have been thoroughly characterized, the cathelicidins and the 
defensins. 
Cathelicidins are not as widespread as defensins, since they recognize a 
more ancient origin [58]. They have been described in lizards, birds, fish and 
certain mammals. They are      α-chained peptides composed of a highly 
conserved N-terminal domain, called the cathelin-propart, and of a C-
terminal antimicrobial domain. Therefore, the name cathelicidin derives 
from cathelin connected with a microbicidal peptide. 
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In humans only one cathelicidin has been described and called human 
cationic antimicrobial peptide (hCAMP18), consisting in 170 aminoacids and 
genetically expressed on chromosome 3 [59]. 
Initially described as a protein synthesized by the bone marrow, it is now 
reported to be also excreted by cutaneous keratinocytes during 
inflammation. 
After digestion by the neutrophils’ serine protease a small peptide, called LL-
37, is involved in the immune modulation activity. hCAMP18/LL-37 
cathelicidin is produced by different cell types, including myeloid cells, 
neutrophils, mast cells, monocytes, epithelial cells of the colon, urinary tract 
and respiratory mucous membranes. 
Defensins are a family of small-sized ß-chained peptides whose molecular 
weight ranges from 3,5 to 4,5 kDa and include 6 cysteine residues which can 
create disulfide bridges [60]. There are three different families of defensins 
according to the position of the disulfide bridges: α, ß and ø-defensins [61]. 
α-defensins are composed of 29 to 35 aminoacids and are characterized by 
1-6, 2-4 and 3-5 cystein disulfide bridges. There are 6 Human α-defensins. 
Four of them are expressed in neutrophil granules, and are also referred to 
as human neutrophil peptides HNP-1 through -4. The α-defensins 5 and 6 
(HD5 and HD6) are found in Paneth cells of the small intestine and in the 
epithelial cells of the female urogenital tract [62]. 
ß-defensins are characterized by 1-5, 2-4, 3-6 cystein disolfide bridges. There 
are six human   ß-defensins, but it is believed that others could be discovered. 
They are produced by epithelial cells [57]. 
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HBD-1 is constitutively expressed in the respiratory and urinary epithelia; 
HBD-2 in psoriasic skin but also in urogenital, gastrointestinal and respiratory 
epithelia. 
HBD-3, described for the first time in psoriasis, has been found in all epithelia 
and particularly in saliva and cervicovaginal fluid. HBD-4 has been detected 
in testicles, stomach and uterus, while HBD-5 and HBD-6 have been mainly 
found in epididimus. 
α- and ß-defensins are codified on chromosome 8. 
Ø-defensins are not found in humans and New world primates. On the 
contrary they are mainly found in Old world primates. They are lectin-like 
cyclic octapeptides expressed in leukocytes [61]. 
 
Fig.11: defensins genes and peptides with three-dimensional structures of 
α-, ß- and ø- defensins (from Hazlett L et al [61]) 
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As to ß-defensins, while HBD-1 is constitutively expressed, HBD-2 can be 
induced by IL-1α, interleukin-1ß, TNF-α, interferon-γ, Gram-positive and 
Gram-negative bacteria, C. albicans, M. tuberculosis, LPS. The activity of 
HBD-2 is increased by several bacterial products through the interaction with 
toll-like receptors (TLRs) 2 or 4 [63]. 
AMPs play their role with a direct antimicrobial activity thanks to their 
electrostatic interaction with the negatively charged phospholipids on 
bacterial membranes, but they are also capable of immunomodulatory 
functions. Both cathelicidin hCAMP18/LL-37 and defensins perform a 
chemoattractive action on monocytes, neutrophils and CD4+ lymphocytes 
and stimulate the production of other chemokines. 
 
Fig.12: many bacterial molecules can activate α- and ß-defensins, which 
recall innate and adaptive immune cells due to a chemoattractive activity. 
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 They are also able to modulate the activity of the dendritic cells and the 
expression of their epitopes. Defensins can induce the maturation of the 
dendritic cells towards TLR-4. Thus AMPs represent a bridge between the 
innate immune system and the adaptive immune system. 
Defensins’ activity has been widely described in the international literature 
with special regards to plants, insects and humans [64]. 
Plant defensins, for example, exhibit antifungal activity against a broad range 
of phytopathogenetic fungi [65], most insect defensins identified so far show 
antibacterial activity against Gram-positive bacteria, Gram-negative 
bacteria, while yeast and filamentous fungi are less sensitive to insect 
defensins. 
In humans it is debated whether funtional impairment or enhancement of 
AMPs can influence the clinical evolution of several diseases, among which 
infective and chronic inflammatory diseases. 
Defensins are known for their activity against certain viruses, like for example 
the Human Immunodeficiency Virus (HIV), the Human Papilloma Virus (HPV), 
Cytomegalovirus (CMV) or against certain bacteria, like Mycobacterium 
tuberculosis or Pseudomonas aeruginosa [61]. 
For antibacterial activities, ß-defensins have proved to be effective in fighting 
S.aureus,  E.coli and M. tuberculosis [66]. 
For antifungal activities, ß-defensins have turned out to be expecially active 
against C.albicans and other Candida species, with the exception of C. 
glabrata [67].  
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For antiviral activities α-defensins are capable of inhibiting Human 
Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV) [68]. 
For anti-parasite activities, several studies have reported that defensins are 
active against Toxoplasma gondii and Tripanosoma cruzi [69].  
A decrease in number or function of defensins could increase the host’s 
susceptibility to infections. 
On the contrary, in autoimmune or disregulated immune responses the 
AMPs’ activity seem to be altered, as it has been shown in Psoriasis and 
Atopic dermatitis. In psoriasis LL-37 production is increased and is associated 
with inflammation of the skin, while in Atopic dermatitis the decreased 
presence of defensins is linked to infection by Stafilococcus aureus. 
Among respiratory diseases, the major susceptibility to bacterial infection 
recorded in Fibrosis cystica may be linked to the production of salts within 
the alveolar fluid. Alterations of AMPs’ activity is also reported in idiopathic 
pulmonary fibrosis, alveolar proteinosis, acute respiratory distress 
syndrome, lung transplantation, allergic rhinitis. 
It seems that functional and epigenetic defects of defensins’ expression 
could be a determining factor in the pathogenesis of some autoimmune 
diseases, including diabetes mellitus and Crohn’s disease [57]. 
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Fig.13: functions of AMPs in inflammatory diseases. Various cell types are 
activated by microbes and inflammatory mediators, causing the production 
and release of AMPs. These peptides show different functions, including 
antimicrobial activity and modulation of the inflammatory response. 
However, an alteration in the activity of AMPs leads to the development of 
infectious or inflammatory diseases (from Guaní-Guerra et al [57]) 
 
Recently a connection between defensins and hyaluronic acid has been 
shown, especially in the skin. 
Hyaluronic Acid (HA) has an important role in tissue biomechanics and 
intercellular signaling. The dimension of HA molecule is important, since the 
high weight polymer (over 500 kDa) shows reparative and protective 
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functions towards cells, while on the contrary the fragments generated by 
enzymes (hyaluronidasis) or by free radicals show a pro-inflammatory and 
pro-angiogenetic effect. 
In recent years some papers have demonstrated an in-vitro capability of HA 
olysaccharydes to induce HBD-2 when in contact with keratinocytes [70]. 
This discovery has shown how defensins are important in protecting the skin 
from infective agents after traumatic lesions or tissue damage, which 
generate HA fragments. HA acts through the toll-like receptors 2 and 4 and 
it is no more considered to be an inert molecule, but an important biological 
effector in cell migration and proliferation, angiogenesis, wound healing and 
perhaps tumour diffusion. 
It has been noticed that the lenght of HA fragments is crucial in the definition 
of their function, since HA is a molecule with rigid dysaccharydes sequence 
and information can be carried only by the dimension of its polymers.  
Gariboldi et al have shown how a low-weight polymer of HA can stimulate in 
vitro and in vivo production of beta-defensins through TLR-2 and TLR-4 in 
keratinocytes [70]. 
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Fig.14: LMW-HA-induced ß2-defensin expression in human keratinocytes 
through the toll-like receptors 2 and 4 (from Gariboldi et al [70]) 
 
 
A particular attention is being now turned to brain and neurological 
degenerative diseases, like Parkinson’s disease and Alzheimer’s disease, in 
which a chronic inflammatory response is linked to the apoptotic process of 
neurons. Since HA is a constituent part in the process which regulates 
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neuronal hydradation and electrolytes exchange, it seems that defensins 
could have a protective role in preventing neuronal apoptosis. 
Recently the international literature has been focusing on the role of 
defensins in the oral cavity and their association with several mucosal and 
gingival diseases. 
Common mucosal oral lesions include candidiasis, recurrent herpes labialis, 
erythema migrans, hairy tongue, recurrent aphtous stomatitis and Oral 
Lichen Planus. 
The oral cavity is an environment in which antimicrobial peptides fulfil the 
important function of maintaining balance between health and disease. A lot 
of AMPs have been cited in the oral literature, being the α-defensins mainly 
epressed in neutrophils, the ß-defensins in the epithelium and the LL-37 
cathelicidin in both epithelium and neutrophils. 
Defensins have been found in oral tissues, salivary glands, salivary secretions, 
crevicular fluid. 
In the oral cavity HBD-1 was described for the first time in 1998 [71]. Up to 
now, only a small group of studies has investigated HBD-1 or HBD-2 in the 
saliva of patients with OLP or other mucosal conditions [72][73]. 
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   3.1.2  ORAL LICHEN PLANUS 
Lichen Planus is a common, chronic cutaneous disorder which often affects 
the oral mucosa. Since skin lesions resemble the lichens growing on rocks, 
Wilson was the first who named the disease after these vegetable organisms 
[74]. Even though the word Lichen Planus can suggest a fungal condition, it 
is now accepted that it is a chronic autoimmune disease. 
The relationship between the disease onset and the feeling of stress/anxiety 
experienced by patients has been widely discussed but it is still controversial. 
Most patients with lichen planus are middle-aged adults and the ratio of 
women to men is 3:2. It is thought that about 1% of the population may have 
this condition [75]. 
The skin lesions of lichen planus have been described as purple, itchy, 
poygonal papules. They usually affect the flexor surfaces of the extremities. 
Excoriations may not be visible, despite the fact that the lesions itch, and 
become sore when the patient scratches them. 
A thorough examination of the skin surfaces of the papules will reveal the 
presence of a fine, lacelike network of white lines known as Wickham’s 
striae.  
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Fig.15: the glans penis, the vulva and the nails can be also affected (from 
Neville BW et al [74]). 
The majority of patients with dermal lichen planus show associated oral 
lesions. On the contrary, only 40% of patients with oral manifestations have 
skin lesions as well. 
In the oral cavity, the disease has a somewhat different clinical appearance 
from the presentation on the skin: it is typically characterized by lesions 
consisting of radiating white or gray, velvety, thread-like papules in a linear, 
annular or retiform arrangement forming classic lacy, reticular patches, rings 
and streaks over the buccal mucosa and, to a lesser extent, on the lips, 
tongue and palate. 
These lesions do not cause significant symptoms in the majority of patients, 
while in others there may be a complaint of a burning sensation in the 
involved area [76]. 
Reticular lichen planus is the most frequent form of the disease. This variant 
usually does not trigger any symptom and involves the posterior buccal 
mucosa bilaterally. Other oral mucosal surfaces may also be involved 
concurrently, such as the lateral and dorsal tongue, the gingivae, palate, and 
vermilion border. 
 80 
 
Reticular lichen planus is thus named because of its characteristic pattern of 
interlacing white lines (Wickman’s striae). These lesions are typically 
variable, they wax and wane over weeks or months. 
 
Fig.16: reticular OLP; the typical Wickman’s striae are evident on buccal 
mucosa 
A hyperplastic form of lichen planus may also occur on the oral mucosa, 
generally appearing as well-circumscribed, elevated white lesion resembling 
leukoplakia. In such cases biopsy is usually necessary to make a diagnosis. 
 
       
Fig.17: bilateral white patches on buccal mucosae are the hyperplastic form 
of OLP 
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An atrophic form of lichen planus occurs with some frequency and clinically 
appears as smooth, red, poorly defined areas, often but not always with 
peripheral striae evident.  
      
Fig.18: atrophic OLP; erythema and epithelial atrophy are evident on buccal 
mucosa and on the dorsum of tongue 
Erosive lichen planus, although not as common as the reticular form, is more 
significant for the patient because the lesions are usually symptomatic. 
Clinically, there are atrophic, erythematous areas with central ulceration of 
varying degrees. 
     
Fig.19: erosive and ulcerative OLP; epithelial erosion with the formation of 
painful ulcers are distinguishing features of this OLP form 
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If the erosive feature is severe, epithelial separation from the underlying 
connective tissue may occur. This results in the relatively rare presentation 
of bullous lichen planus. 
  
Fig.20: bullous OLP; this form must be distinguished from vesiculo-bullous 
diseases like pemphigus vulgaris or mucous membrane pemphigoid 
The clinical forms can be grouped into two families: the so-called “white” 
lichen planus, which includes the papular, the reticular and the hyperplastic 
form, and the “red” lichen planus, which comprises the atrophic, the erosive 
and the bullous forms. 
The red forms are those in which inflammation is more represented, they are 
often symptomatic and may undergo malignant transformation, even 
though it is uncommon. 
The histopathologic features of lichen planus are characteristic but may be 
not specific, because other conditions, such as lichenoid drug reaction, 
lichenoid amalgam reaction, oral-versus-graft disease (GVHD), lupus 
erythematosus (LE), chronic ulcerative stomatitis and oral mucosal cinnamon 
reaction may also show a similar histopathologic pattern. 
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Varying degrees of ortokeratosis and parakeratosis may be present on the 
surface of the epithelium with thickening of the granular layer, depending on 
whether the biopsy specimen is taken from a red or white lesion. 
The thickness of the spinous layer can also vary. The rete ridges may be 
absent or hyperplastic, but they classically have a pointed or “saw-toothed” 
shape. 
Destruction of the basal cell layer of the epithelium (hydropic degeneration) 
is also evident. This is accompanied by an intense, bandlike infiltrate of 
predominantly T lymphocytes immediately subjacent to the epithelium. 
Degenerating keratinocytes may be seen in the area of the epithelium and 
connective tissue interface and have been termed Civatte bodies. 
Degeneration of the basal keratinocytes and disruption of the anchoring 
elements of the epithelial basement membrane and basal keratinocytes (i.e. 
hemidesmosomes, filaments, fibrils) weakens the epithelium-connective 
tissue interface. As a result, histologic clefts (Max-Joseph spaces) may form, 
and blisters on the oral mucosa (bullous lichen planus) may be seen on 
clinical examination. B-cells and plasma cells are uncommon findings. 
Immunoglobulin or complement deposits are not a distinguishing feature of 
OLP. In some istances, fibrinogen and fibrin are deposited in a linear pattern 
in the basement membrane zone. The pattern of fibrinogen deposition, in 
the absence of fluorescence by other reagents, is sufficiently unique to be 
used as a diagnostic criterion for oral mucosal lichen planus. 
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Fig.21: histopathologic features of OLP. A chronic band-like lymphocitic 
infiltrate is localized at the interface between epithelium and connective 
tissue, rete ridges are atrophic 
There is some controversy surrounding its malignant potential. There seems 
to be a slightly higher incidence of oral squamous cell carcinoma in patients 
with Oral Lichen Planus than in the general population. The actual overall 
frequency of malignant transformation is low, ranging from 0,3 to 3%. The 
forms that more commonly undergo malignant transformation are the 
erosive and atrophic ones. 
At present there is no cure, although various agents have been tried. Medical 
treatment of OLP is essential for the management of painful, erythematous, 
erosive, or bullous lesions. The main aim of current OLP therapy is to relieve 
painful symptoms, heal oral mucosal lesions, reduce the risk of oral cancer, 
and maintain good oral hygiene. As it is an autoimmune mediated condition, 
corticosteroids are recommended. In patients with recurrent painful disease, 
another goal is to prolong their symptom free intervals. The main concern 
over current therapies is represented by local and systemic adverse effects 
and lesion recurrence after treatment is suspended. Patients should be 
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followed up periodically, particularly those affected by the erosive or 
atrophic forms and those who also have a history of alcohol and tobacco 
abuse, because of the risk of malignant transformation. 
 
Although in vitro studies into HBDs in oral epithelium cells are well 
documented, oral epithelium has only scarcely been the subject of in vivo 
investigations. Published studies have shown that HBD-2 peptide is 
expressed mainly in granular and keratinized layers, but is not easily seen in 
the non-keratinized oral epithelium, including buccal and junctional 
epithelia. Abiko et al [78] found that in 43% of cases of lichen planus, there 
was a positive immunohistochemical staining for HBD-2 in the spinous layer. 
Staining was marked even in lichen planus with non-keratinized epithelium. 
The border of the area with transition of the non-keratinized normal 
epithelium into lichen planus separated the positively stained areas from 
those showing no staining. The immunohistochemical localization of HBD-2 
peptide in lichen planus was stronger and wider than in normal epithelium. 
The site of HBD-2 epression was faint and restricted to the keratinized area 
and to part of the granular layers in normal oral epithelium. Intense staining 
of HBD-2 in a lower spinous layer of lichen planus was often observed. The 
presence of HBD-2 is linked to the presence of inflammatory infiltration. 
Specific inflammatory conditions related to lichen planus may be involved in 
the upregulated expression of HBD-2. The inflammatory infiltrate in lichen 
planus is composed of lymphocytes, predominantly T-cells. These T-cells 
produce many types of cytokines, which, in turn, stimulate the production of 
other cytokines in epithelial cells. Expression of HBD-2 is upregulated by 
stimulation of cytokines, including TNF-α and IL-1- In lichen planus, TNF-α is 
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increasingly produced in both sub-epithelial inflammatory infiltrate and 
epithelial cells. Upregulated expression of HBD-2 in lichen planus may be 
involved in increased production of TNF-α. 
In a following paper, Nishimura, Abiko et al [79] reported that the localization 
pattern of HBD-3 mRNA in oral tissues was almost the same as that of HBD-
2. Previous papers had shown that HBD-2 expression was involved in 
keratinocyte differentiation. HBD-3 mRNA was localized in the upper spinous 
and granular layers in normal oral epithelium. These results may indicate that 
HBD-3 expression is also involved in keratinocyte differentiation. 
Although both HBD-2 and HBD-3 are upregulated by inflammatory 
stimulation such as the one triggered by cytokines and bacteria, cytokines 
that stimulate upregulation are different. In contrast to HBD-2 that was 
induced by TNF-α, no regulation of HBD-3 was found after stimulation, but 
HBD-3 was induced by IFN-γ. IFN-γ production has been also confirmed in 
recent papers about lichen planus. The upregulated expression of HBD-3 in 
lichen planus in the present study may be involved in the production of      
IFN-γ. 
 
  3.1.3  BURNING MOUTH SYNDROME 
Burning Mouth Syndrome has been previously described in this dissertation. 
It affects mainly women who present with a chronic burning or tingling 
sensation in their mouth with no local or systemic causes that could explain 
the symptoms. 
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Recent theories link the onset of this disease to both a psychosomatic 
alteration in pain perception and a peripheral trigeminal and lingual nerve 
fibers dysfunction. 
It could be interesting to check if an alterated level of defensins may be one 
of the main causes in the pathogenesis of the alteration of the nerve fibers 
metabolism inside the oral cavity. 
 
      3.2     AIM  
This work focuses on the possible role of defensins in the pathogenesis and 
maintenance of several oral pathologies. It is included in a larger 
departmental project which analyses the role of defensins in dermatology, 
ginecology, ophtalmology and neurology. 
The aim of this research is to investigate if the expression of defensins may 
play a statistically significant role in the pathogenesis of oral conditions.  
The most representative oral pathologies were chosen among different 
cathegories: Periodontal disease among infective disorders, Diabetes 
mellitus and its oral manifestations among metabolic diseases, Oral Lichen 
Planus for autoimmune diseases and Burning Mouth Syndrome among the 
neuropathic and psychosomatic disorders of the oral cavity. 
This study reports the results for Oral Lichen Planus and Burning Mouth 
Syndrome. 
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        3.3    MATERIALS AND METHODS 
 
The current study was conducted in the Department of Surgical and 
Morphological Sciences, University of Insubria, ASST dei Sette Laghi, Unit of 
Oral Pathology, Dental Clinic, Varese, Italy. 
A total number of 35 patients were recruited for this study. 
Among them, 17 were affected by Oral Lichen Planus (OLP), 9 by Burning 
Mouth Syndrome (BMS) and 9 were included as a control group (CTRL). 
Inclusion criteria for the OLP group were the presence of a positive 
histopathologic diagnosis of the disease, age greater than 30, while patients 
undergoing topical or systemic therapies were excluded from the 
recruitment. 
Inclusion criteria for the BMS group were the final diagnosis of a primary 
idiopathic burning pain according to the guidelines of the international 
literature [45], age greater than 45 and female sex, whereas the presence of 
other concomitant mucosal pathologies, such as a secondary burning pain 
linked to systemic conditions or other neuropathies, were exclusion criteria. 
The control group (CTRL) included healthy patients with demographic 
similitaries to the other two groups, especially considering age and F:M ratio. 
Each patient underwent a dental examination by a clinician who was the 
same throughout the whole study. 
Firstly, a sample of saliva was collected through the spitting method for 
about 1 minute in a sterile test tube. 
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Secondly, a sterile paper cone was inserted for at least 30 seconds into the 
gingival sulcus nearby a dental element chosen through randomized criteria. 
The procedure was carried out 4 times per patients, each time near a 
different dental element, in order to collect a sufficient quantity of crevicular 
fluid. Furthermore, each OLP patients was also evaluated for the clinical 
appearance of the lesions, subdividing the population into two subgroups: 
red OLP, when patients showed an atrophic or erosive variant of the disease; 
white OLP, when reticular and hyperplastic forms were detected. 
Collected specimens were sent to the Biochemistry Laboratory to be 
analysed. 
The samples were stored at a temperature of – 20 °C before examination. 
Human ß-Defensin 2 Elisa Kit protocol was used for this study (EK-072-37 
Phoenix Pharmaceuticals, Inc.). The immunoplate was precoated with anti-
Human ß-Defensin 2 Capture Antibody and the nonspecific binding sites 
were blocked. Human ß-defensin 2 in the standard solution or in the sample 
could bind to the capture antibodies immobilized in the wells. 
After washing procedure, the Biotinylated anti-Human ß-defensin 2 
Detection Antibody which could bind to Human ß-defensin 2 trapped in the 
wells was added. After washing, the Streptavidin-Horse-radish Peroxidase 
(SA-HRP) which catalyzes the Substrate Solution (TMD) was added. The 
enzyme-substrate reaction was terminated by the addition of a stop solution. 
The intensity of the colour was directly proportional to the amount of Human 
ß-Defensin 2 in the standard solutions or samples. 
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Fig.22: graphic representation of the HBD-2 ELISA-kit protocol 
 A standard curve of Human ß-Defensin 2 with known concentration could 
be generated accordingly.  
 
Fig.23: generation of a standard curve of HBD-2 
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Comparative statistics among the different groups was performed with T-
Student independent variables test for parametric values and the Chi-square 
test for non parametric values by using the IBM SPSS version 20.0, SPSS Inc, 
Chicago, IL, USA. 
 
       3.4   RESULTS 
A total number of 35 saliva and crevicular liquid samples were analysed 
with ELISA protocol. 
17 patients were affected by Oral Lichen Planus (OLP group), 11 females 
and 6 males. 
9 patients were affected by Burning Mouth Syndrome (BMS group), only 
women. 
9 patients were included in the control group (CTRL group), 7 women and 2 
males. 
 
Plot 6: epidemiologic data of patients recruited in the current study 
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The OLP group ELISA test for detection of HBD-2 in saliva ruled out a mean 
value of 4341,85 +/- 2748,68 pg/ml, with a registered miminum value of 
304,28 pg/ml and a maximum of 10890,56 pg/ml. The mean value of HBD-2 
reported among the OLP group in the crevicular fluid was 4157,37  +/- 
2620,59 pg/ml with a registered minimun value of 444,65 pg/ml and a 
registered maximum value of 8552,84 pg/ml. 
 
Plot 7: HBD-2 salivary registered values in OLP group 
Table 4: salivary and crevicular fluid HBD-2 registered values in OLP group 
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The BMS group ELISA test for detection of HBD-2 in saliva ruled out a mean 
value of 3789,05 +/- 1565,83 pg/ml, with a registered minimum value of 
1703,43 pg/ml and a registered maximum value of 7047,26 pg/ml.  The mean 
value of HBD-2 reported in the BMS group in the crevicular fluid was 3314,94 
+/- 1064,27 pg/ml with a registered minimun value of 1703,43 pg/ml and a 
registered maximum value of 5066,56 pg/ml. 
 
 
Plot 8: HBD-2 salivary registered values in BMS group 
Table 5: salivary and crevicular fluid HBD-2 registered values in BMS group 
 
 
BMS 
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The CTRL group ELISA test for detection of HBD-2 in saliva ruled out a mean 
value of 3268,95 +/- 1886,90 pg/ml, with a registered minimum value of 
428,01 pg/ml and a registered maximum value of 6242,46 pg/ml.  The mean 
value of HBD-2 reported in the CTRL group in the crevicular fluid was 4399,70 
+/- 3889,23 pg/ml with a registered minimun value of 530,23 pg/ml and a 
registered maximum value of 11767,84 pg/ml. 
 
Plot 9: HBD-2 salivary registered values in CTRL group 
Table 6: salivary and crevicular fluid HBD-2 registered values in CTRL group 
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One-way ANOVA test was used to compare the values of salivary HBD-2 
registered among the three groups. There was not any statistically significant 
difference among the groups with regards to the production of HBD-2 
(p=0,523). 
The same test was performed to compare the values of gingival HBD-2 
registered among the three groups. There was not any statistically significant 
difference among the groups with regards to the production of HBD-2 
(p=0,897). 
However, the distribution of values registered in saliva and crevicular fluid 
was strictly correlated. Paired sample correlation test was used to compare 
the associated variance of salivary and gingival values within patients 
(p=0,000). 
Therefore, the presence of corresponding values in saliva and crevicular fluid 
showed how the ELISA detection method was correct and that saliva and 
crevicular fluid contained an equivalent quantity of HBD-2 in the same 
patient. 
Nevertheless, observing the scatter plot and the box plot (Plots 10-11) it 
could be possible to notice that while the mean values were similar among 
the groups, even if registered values were slightly higher in OLP and BMS 
than in the CTRL group, in OLP there was a dycotomic pattern of distribution 
between a subgroup showing very high values (>3500 pg/ml) and another 
subgroup with values similar to those detected in the other two groups 
(<3500 pg/ml). 
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Plot 10: scatter plot of HBD-2 salivary values 
 
                                                  OLP      BMS       CTRL 
Plot 11: box plot of HBD-2 salivary values 
The clinical evaluation of OLP ruled out the presence of 10 white OLP and 7 
red OLP. 
A statistical non-parametric comparison was made between the 
classification of OLP based upon the clinical evaluation and the results of the 
ELISA test defined as low (<3500 pg/ml) or high (>3500 pg/ml). There was a 
strong statistical correspondance (p=0,002). 
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Table 7: contingency table clinical * ELISA groups 
 
SALIVA ELISA Total 
< 3.500  3.500 
Clinical 
White 9 1 10 
Red 1 6 7 
Totale 10 7 17 
 
The same analysis was made for crevicular fluid and proved to be statistically 
significant (p=0,000), confirming the association between salivary and 
gingival values 
 
Table 8: contingency table clinical * ELISA groups 
 
CREVICE ELISA Total 
<3.500 >3.500 
Clinical 
White 10 0 10 
Red 1 6 7 
Total 11 6 17 
 
ANOVA analysis was performed by comparing the salivary values in relation 
to the dycotomic clinical classification. There was a statistically significant 
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difference between salivary HBD-2 values registered in the red OLP subgroup 
and those found in the white OLP subgroup (p=0,000). 
The same result was obtained performing an ANOVA test to compare 
crevicular fluid values in relation to the clinical classification (p=0,000). 
 
 
 
        3.5   DISCUSSION 
Antimicrobial Peptides (AMPs) represent a recent interesting field of 
research in immunobiology and medicine, even though they are an 
evolutionary ancient means of defense by the host through the innate 
immune system. 
In recent years the international literature has shown that not only do they 
play a special role in fighting off infective agents, but also in 
immunomodulatory functions and wound healing. A reduced production or 
function of these small peptides imply the onset of infective disease, wound 
superinfection or cancer, while on the contrary an excess in their presence 
or activity seems to be linked to autoimmune diseases. 
ß-defensins are mainly expressed in the mucosal barriers throughtout the 
human body, like in the bowel, the cute, the genitourinary tract and oral 
mucosa. 
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Several studies tried to establish the role of ß-defensins in the pathogenesis 
of periodontal disease and other oral disorders, but only a few papers can be 
found in the literature. 
In this study the choice was to study the role of HBD-2, which is an inducible 
and not constitutionally expressed defensin, in the pathogenesis of the most 
frequent autoimmune disease of the oral cavity, Oral Lichen Planus (OLP). 
17 OLP patients, with a positive histopathologic diagnosis of the disease, 
were recruited into this study in order to measure the relative quantity of 
HBD-2 in their saliva and crevicular fluid. The values were compared with 
those collected from a group of 9 patients affected by the Burning Mouth 
Syndrome (BMS), the most enigmatic neuropathic disorder of the mouth, 
and with a control group (CTRL) of 9 patients. 
There was not any statistically significant difference between the groups 
(p=0,523; p=0,897), both the Burning Mouth Syndrome and Oral Lichen 
Planus. However, the latter seemed to show increased mean levels of HBD-
2. Besides, the study highlighted the role of HBD-2 in the maintenance and 
intensity of the inflammatory component in Oral Lichen Planus. 
Patients affected by OLP showed a dycotomic distribution of values: while 10 
of them showed similar values to those found out in the other two groups, 7 
patients expressed high levels of HBD-2, and 3500 pg/ml was the threshold 
to distinguish the subgroups. 
During the dental visit the clinician classified OLP patients into two groups 
according to the clinical presentation of the disease: reticular and 
hyperplastic OLP forms were considered to be associated with a low level of 
 100 
 
disease and inflammation, whereas atrophic and erosive forms were related 
to a high degree of inflammation. 
There was a statistical significant correlation between the clinical and 
numeric classification of the patients (p=0,004; p=0,001), and the expression 
of HBD-2 was higher in the red OLP group than in the white OLP group 
(p=0,000; p=0,000). 
In conclusion, this study shows that HBD-2, which is an inducible molecule, 
represents an index to assess active inflammation and it is probably linked to 
the presence of the typical band-like CD8+ infiltrate in Oral Lichen Planus. 
HBD-2 can be used as a parameter to monitorize the degree of disease 
activity and inflammation. Besides, the use of Hyaluronic acid in the 
treatment of several inflammatory diseases of the oral cavity should be 
thoroughly investigated because the different fragments derived from 
enzymatic digestion or topical products could have completely different 
effects according to their molecular weight. Therefore prescription should be 
made after careful evaluation of possible side effects and biological activity.  
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4.    3rd STUDY: HELICOBACTER PYLORI IN PERIODONTAL 
POCKETS AND SALIVA: A POSSIBLE ROLE IN GASTRIC INFECTION 
RELAPSES? 
A PRELIMINARY STUDY IN NORTHERN ITALY. 
 
 
         4.1    BACKGROUND 
Helicobacter pylori (HP) is a widespread bacterium, which is found within water and 
in some animals’ biological fluids, and it is the responsible for chronic gastritis and 
other gastric diseases [80]. 
Helicobacter pylori is known to be associated with chronic gastritis in 90% of cases, 
but it has also been described in acute gastritis, peptic ulcer and gastric cancer. This 
bacterium has adapted to thrive in the acidic environment of the stomach and this 
requires additional virulence factors, such as urease production, which is a direct 
marker for diagnosis. Despite the fact that infection incidence has decremented in 
recent years, about half of the world population is still infected. Moreover, 
treatment resistance and relapses represent a threatening issue to be dealt with 
[81]. 
 
4.1.1  History 
In 1886 Prof. W. Jaworski was the first one who described a helical bacterium in 
gastric washings which was originally called Vibrio rugula. He suggested a 
pathogenic role in gastric infection. Bizzozzero detected the presence of an 
infectious agent in animals’ stomach. 
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However, these discoveries were confined to Europe. In 1954 the American 
gastroenterologist Palmer failed in his attempt to find bacteria in gastric fluid from 
several patients. 
The early tests carried out to demonstrate the presence of HP were doomed to fail 
because there were not homogeneous culture methods. 
In 1979 Warren described the presence of a bacterium in the superficial epithelium 
from several gastric biopsies. This discovery was sensational, since it had always 
been thought to be impossible until then the possibility of a bacterial proliferation 
in the stomach and the gastric lumen was dogmatically considered as fully sterilized 
by gastric acids. 
Warren was strongly opposed by the medical community, but in 1981 Barry 
Marshall supported him in developing an adequated culture field for the bacterium. 
After initial failure, they published a paper in Lancet suggesting a first-line therapy 
with Bismuth salts and amoxicillin or tetracycline [82]. 
Warren was so strongly convinced that his own theory would be effective that he 
infected himself by ingesting bacterial cultures, developing a well-documented 
gastritis that was successfully treated. Originally called Campylobacter-like 
bacterium, it was quite different from Campylobacter due the presence of 
numerous flagellae and high expression of urease production. In 1989 Goldwin 
called the bacterium Helicobacter pylori. In 2005 Robin Warren and Barry Marshall 
won the Nobel Prize. 
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4.1.2   Helicobacter pylori 
Helicobacter pylori (HP) is a Gram-negative, microaerophilic bacterium, which 
shows a helicoidal shape in its active form, while on the contrary it exhibits a coccoid 
shape during latency. It is 2,5-5 x 0,5mm long and has 5-6 unipolar flagellae. 
 
 
Fig. 24: Helicobacter pylori is equipped with multiple flagellae 
It shows intense catalase, oxydase and urease activities. 
It is equipped with a slighty toxic lipopolysaccharide enriched in Lipid A, while the 
glucidic portion contains analogous sequencies to Lewis X and Y antigens, widely 
distributed within cell surfaces in human body: this could explain the autoimmune 
response which usually contributes to mucosal damage. 
The natural habitat for HP is the gastric mucosa, and this is possible thanks to its 
highly expressed urease activity, which also is a primary marker for diagnosis.  
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4.1.3   Epidemiology 
The prevalence of HP infection has changed in recent years and has diminuished 
with peptic ulcers and gastric cancer. However, about half of the worlwide 
population is still infected, with about one-third in western countries and over 50% 
in Southern and Eastern Europe, South America and Asia. In developing countries 
the infection rate is between 70 and 90% and is generally acquired during infancy, 
while in Western countries it is between 25 and 50% during infancy [83].  
In developed countries, upper-class people with higher and economical standards 
of life are less affected by this infection, while it seems that individuals migrated 
from countries in which the infection is diffuse are more hitten. This is due the fact 
that one main way of transmission seems to be oral and/or oro-foecal, thus the lack 
of primary higienic services and clean water play an important causal role. The 
second way of transmission seems to be linked to the use of infected endoscopes 
or instruments. 
Geographic factors, ethnic background and age greatly influence the epidemiology 
of the infection, but the low social and economical status represents the key factor 
in many cases. 
 
Fig. 25: epidemiologic data from the international literature 
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4.1.4   Pathogenesis 
HP infection triggers an inflammatory response which is not able to eradicate 
bacterial colonization but, on the contrary, becomes persistent and damages the 
lining mucosa. HP binds to the MHC type II complex of gastric epithelium, causing 
cell apoptosis. The first site of infection is the gastric antrum, where acid-secreting 
cells are absent. 
Disease progress depends on different factors, like bacterial genomics and 
adaptability, host defenses and immune status, genetic predisposition, familial 
susceptibility to gastric cancer, smoke and food habits, especially large consumption 
of salt and meat. 
The first step is the colonization of the gastric mucosa, due the interaction between 
bacterial adhesins and glycans expressed by the epithelium surface. 
Urease activity transforms urea into ammonium and carbon dioxide, neutralizing 
gastric acids. 
Furthermore, the bacterium produces several virulence factors, which are 
responsible of intracellular pathways alteration and pro-inflammatory cytokines 
production: CagA, VacA, Hsp-B and duodenal promoting gene A. These factors are 
associated with increased incidence of gastritis and gastric cancer [84]. 
 
4.1.5   Clinical features 
HP infection is typically associated with active chronic gastritis, but only 10-15% of 
infected patients develop a gastric ulcer, because of more severe bacterial virulence 
factors and individual predisposition. 
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While in the stomach HP acts directly against gastric mucosa, in the duodenum it 
exhibits an indirect mechanism. 
The infection in the gastric antrum determines an increased production of gastrin 
and a reduced one of somatostatin. The increased acid production within the fundus 
causes duodenal ulcer and gastric metaplasia, which leads to an increased 
colonization of HP. In addition, HP decreases the production of bicarbonate in the 
duodenal tract. 
HP is also associated with acute gastritis: nodular gastritis, follicular gastritis, 
lymphocytic gastritis, haemorrhagic gastritis, granulomatous gastritis, hypertrophic 
gastritis and Ménétrier disease. 
Other clinical manifestations of HP infection are the non-ulcer dyspepsia, 
multifocal gastric atrophy and intestinal metaplasia, gastric adenoma and 
hyperplastic polyps. 
In 1994 the WHO classified Helicobacter pylori as a cancerogenic agent, and the IARC 
defined it as a first-class carcinogenic agent [85]. 
Cancerogenesis begins within the context of a pre-malignant lesion (atrophic 
gastritis, intestinal metaplasia and dysplasia, with a rate of 0,8%, 1,8% and 32,7%). 
A specific role in cancer development is played by the presence of acetaldheyde, 
which is increased in HP infection and in alcohol consumption. 
It should be also underlined that HP is statistically associated with gastric lymphoma 
[86]. 
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Fig.26: pathogenesis of gastric cancer in a patient with HP infection 
 
HP infection is also correlated to several extragastric diseases, in which it seems to 
act as a trigger for their development. 
These pathological entities include syderopenic anaemia, idiopathic 
thrombocytopenic purpura, pancreatic tumours, dermatological diseases 
(expecially chronic urticaria), obesity, cardiovascular and neurological diseases, 
 108 
 
gynecological diseases, autoimmune tyroiditis, oropharingeal diseases, bowel 
diseases [87]. 
 
 
Fig.27: extra-gastric manifestations of HP infection 
 
4.1.6  Diagnosis 
Two kinds of diagnostic procedures allow to detect HP infection: invasive and non-
invasive methods. 
Among the invasive procedures, esophagogastroduodenoscopy with or without 
histological evaluation, microbiological examination and rapid urease test (RUT) 
are indicated. 
The Sydney system is used to obtain 5 topographically determined mucosal biopsy 
samples evaluated by the Sydney score to determine the gastric atrophy grade [88].  
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The rapid urease test can be performed, with an accuracy of 90%. However, patients 
have to suspend PPI for two weeks before the examination and bleeding can 
alterate the histologic results. 
Microbiological examination is only performed in particular cases. Cultures are 
Gram-negative, urease, catalase and oxydase positive. HP is very fragile outside the 
gastric environment and analysis should be performed as soon as possible once the 
procedure has been completed. 
In addition, PCR-RT can be used on gastric biopsies. 
Among non-invasive diagnostic procedures serological procedures can be used: the 
detection of specific serum IgM with ELISA-test, Latex agglutination test and 
Western Blotting Test. IgG can be found in serum or urina, while IgA in saliva, these 
latest two less sensible. 
However, the great disadvantage of this technique is that it does not distinguish 
between active and previous infection. 
Nowadays C-Breath Test Urea (C-BTU) measures urease activity in breath. Patients 
swallow urea labelled with an uncommon isotope, either radioactive carbon-14 or 
non-radioactive carbon-13. 10 to 30 min after ingestion of the urea, the detection 
of isotope-labelled carbon dioxide in exhaled breath indicates that the urea was 
split; this indicates that urease (the enzyme that H. pylori uses to metabolize urea) 
is present in the stomach, and hence that H. pylori bacteria are present [89]. 
For the two different forms of urea, different equipment is required. Carbon-14 is 
normally measured by scintillation, whereas carbon-13 can be detected by isotope 
ratio mass spectrometry or by mass correlation spectrometry. For each of these 
methods, a baseline breath sample is collected before taking the isotope-labeled 
urea, for comparison with the post-urea sample, with a 20- to 30-minute interval 
between them. Samples may be sent to a reference laboratory for analysis. 
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Alternatively, mass correlation spectrometry can be performed as an office-based 
test since breath samples are continuously collected, and results are provided 
immediately within minutes. 
The difference between pre- and post urea measurements is used to determine 
infection. This value is compared to a cut-off value. Results below the value are 
considered negative, those above it positive. The cut-off value itself is determined 
by comparing the results of patients with two or more different detection methods. 
The chosen value is the one which gives the best combination of sensitivity and 
specificity. 
The test measures active H. pylori infection. If antibiotics lower the amount of HP, 
or stomach acidity is less than normal, the quantity of urease present will decrease. 
Accordingly, the test should be performed only 14 days after stopping acid reducing 
medication (proton pump inhibitors, PPI) or 28 days after stopping antibiotic 
treatment. 
It is a easily reproducible test with 88-95% sensibility rate and 95-100% specificity. 
Tests for foecal antigens are also carried out by using anti-catalase monoclonal 
antibodies [90]. This kind of test is not influenced by PPI. 
Guidelines are available at the Acts of the IV edition of Maastricht/Florence 
Consensus [91]. 
 
4.1.7   Therapy 
The problem frequent relapses has urged clinicians to issue adequate guidelines to 
treat HP infection, which were discussed during the Toronto Consensus 
Conference [92]. 
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Therapy is recommended in the following cases: 
- gastric or duodenal ulcer: in this case it prevents further recurrence; 
- chronic gastritis: therapy cures gastritis and relieves symptoms, 
sometimes only partially; 
- early gastric cancer and MALT lymphoma: eradication therapy is the 
preferred initial treatment; 
- non-ulcer dyspepsia; 
- prevention in patients with a high risk of gastric cancer development; 
- metaplasia; 
- extragastric manifestations: especially in vitamin B12 deficiency and 
idiopathic thrombocytopenic purpura. 
It should be noticed that there is no correlation between HP infection and gastro-
esophageal reflux disease [93]. 
Triple therapy, including a Proton Pump Inhibitor (PPI) plus two antibiotics, such as 
clarithromycin and amoxicillin or metronidazole, is the most common treatment of 
choice. 
In recent years the prevalence of resisting bacterial strains drew the attention of 
clinicians to the issue of the worrisome increase in unsuccessful rates in the 
therapeutic protocol. Resistance rate to clarithromycin is around 20%, 20-40% to 
metronidazole while it has remained only 1-3% to amoxicilline. Taking into account 
the high prevalence of clarithromycin resistance, quadruple therapy 
(PPI+bismuth+metronidazole+tetracyclin) is used as an alternative strategy. In 
recent years, there have been reports suggesting sequential therapy (agents 
administered in sequence) and concomitant therapy (non-bismuth quadruple 
therapy) as alternative treatment able to eradication rates similar to PPI-triple 
therapy.  However, the results of recent studies have shown that documented 
eradication rates are at their lowest level in history. This could be due to incomplete 
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elimination of HP, which results in recrudescence of the same strain, or to a new 
infection by a new strain [94]. 
 
Fig.28: recommended therapeutic regimens in eradication of HP gastric infection 
Treatment should last at least 14 days for every patient. 
The choice of protocol should take into account regional resistance to antibiotics. 
The PPI represent fundamental allies to guarantee a correct drug functioning due 
the presence of high conditions of acidity in the environment of the stomach. 
 
Fig.29: flowchart of medication protocol in the treatment of HP gastric infection 
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4.1.8     Helicobacter pylori and the oral cavity. 
Relapses are not uncommon. This leads to the hypothesis of a possible extra-gastric 
reservoir of infection. 
Investigation on a reservoir of HP which could contribute to relapses of gastric 
infection becomes crucial. 
Apart from the stomach, HP has also been found in the distal esophagus, the 
proximal duodenum, the colonic contents, and the oral cavity, including tonsil and 
adenoid tissue [95]. 
Many papers about the relationship between the oral cavity and gastric HP infection 
have been published, with numerous evidence-based studies suggesting that the 
oral cavity may be a potential reservoir for HP [96][97]. 
The presence of HP in the oral cavity was discovered for the first time in 1989 [98]. 
Following studies diagnosed the presence of HP in dental plaque, saliva, tongue, 
tonsil tissue and root canals [99]. 
Some authors believe that HP can live symbiotically with Candida and yeasts, 
enhancing the ability to resist in the difficult environment of the oral cavity. The fact 
that this bacterium has been found in saliva, dental plaques and foeces reinforces 
the opinion that oro-oral and oro-foecal ways of transmission are the most involved. 
Conversely, other scientists have claimed that the oral cavity may not be a reservoir 
of HP. This contention is largely based upon different detection methods for oral 
HP. 
A meta-analysis published in 2011 reported strong connection between the 
presence of HP in the oral cavity and in the stomach [100]. 
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However, triple eradication therapy has no or little effect on oral HP elimination; 
studies have recorded eradication rates for oral infection below 40% [101]. 
The presence of oral HP might diminish the effect of eradication therapy and acts 
as a causal element in the recurrence of HP infection. 
Microbiologic examination is considered the gold standard to evaluate the presence 
of HP within the oral cavity. However it is a technique with low sensibility and 
specificity rates. Sometimes the bacterium can be in the coccoid form, which is not 
detected, and/or with a low number of elements. 
The introduction of the PCR-RT technique allowed researchers to detect HP when it 
is slightly present in saliva or dental plaque. 
In recent years various studies have documented the interaction between HP and 
the oral tissue involved in several oral pathologies. 
Some clinicians refer the presence of HP in periodontal pockets, oral squamous cell 
carcinoma and correlate gastric infection to the insurgence of apthous stomatitis 
[102]. However, other clinicians tend to underestimate the role of HP in the oral 
cavity, but no scientific consensus has been reached so far. 
 
 
      4.2    AIM 
It has been a long time since the scientific community started to speculate upon the 
presence of HP in periodontal pockets as an extra-gastric reservoir responsible of 
gastric relapses after eradication therapy. 
Firstly, it should be borne in mind that there is a difference between recrudescence 
and reinfection. Recrudescence is the relapse due to the action of the same 
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bacterial strain after some months from eradication therapy, while reinfection is 
due to the action of a new bacterial strain. 
In developed countries relapses are mainly due to recrudescence, while in 
developing countries reinfection is more common. 
The international literature reports are very controversial. 
Some papers highlight the presence of HP expecially in patients with low oral 
hygienic conditions, as reported in the study by Mohammed Al Asqah [103]. 
Other authors, like Myriama-Lucrecia Medina have pointed out the presence of the 
bacterium in the oral cavity in association with dyspeptic symptoms [104]. 
On the contrary, Nélio Vega et al have rejected the correlation between oral cavity 
and gastric relapses, claiming that HP in the oral cavity is due to gastro-esophageal 
reflux disease or contaminated food intake [105]. However, the same author has 
described a greater prevalence of HP infection in the oral cavity by comparing social 
and demographic variables, age, geography and economic status. 
Another much-discussed issue is whether eradication therapy for gastric infection 
is capable of eliminating HP from the oral cavity. 
Several studies have shown unsuccessful eradication from the oral cavity because 
of the presence of dental plaque biofilm, which is a very effective barrier against 
antibiotics and drugs. Only periodontal therapy, through dental debridment can 
eliminate resident bacteria, including HP [106]. 
Other studies have stated that periodontal therapy plus eradication therapy could 
prevent gastric relapses more than eradication therapy alone [101]. 
The aim of this study is to evaluate the presence of Helicobacter pylori in a group of 
patients who underwent examination for gastric infection.  
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Firstly it is necessary to compare the presence of HP in patients with negative 
diagnosis of gastric infection versus patients with a positive diagnosis of gastric 
infection. 
Then, the role of periodontal health as a predisposing factor for oral HP infection 
should be thoroughly investigated. 
Finally, the main purpose is to accertain whether the presence of HP within oral 
tissues can represent an extra-gastric reservoir able to contribute to gastric relapses 
after eradication therapy in a significant way. 
 
 
     4.3    MATERIALS AND METHODS. 
This research was conducted at the Department of Surgical and Morphological 
Sciences, University of Insubria, ASST dei Sette Laghi, Unit of Gastroenterology, 
Varese, Italy. 
The experimental protocol was evaluated by the Institutional review Board, 
reference number 19/2015. 
60 patients were recruited into the current study, subdivided into two groups: 30 
patients with a positive result for HP gastric infection with C-UBT examination 
(group A) and 30 patients with a negative result for HP gastric infection (group B). 
An informed consent (see below) was read, understood and signed by all patients. 
A dental clinician performed periodontal examination for every patient. 
Inclusion criteria were the presence of the signed informed consent, compliance 
and good general health conditions; exclusion criteria concerned the intake of 
antibiotics or proton-pump inhibitors for 60 days prior to the breath test. 
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Dental probing showed the presence of periodontal pockets in all four quadrants. 
Afterwards, a paper cone was inserted for 30 seconds into the gingival sulcus near 
the dental element with the deepest probing value registered for each quadrant 
and then sent in a sterile tube to the laboratory for evaluation. 
Saliva was collected through the spitting method for one minute in a sterile tube. 
Specimens were processed to extract and purify DNA by using a method that 
includes two consecutive phases of incubation with lysozime and proteinase K. Once 
extracted, DNA was purified through a silica spin-column (Sigma-Aldrich, St. Louis, 
MO, USA). Quantitative PCR of 16S rRNA genes was performed with the hydrolysis 
probes method to identify and evaluate the amount sequences of 16S rRNA gene of 
the Human Oral Microbiome Database (HOMD 16S rRNA RefSeq Version 10.1). All 
sequences were aligned to find either a consensus sequence or less preserved spots, 
useful to optimize the specificity of primers and dual labelled hydrolysis probes. 
Absolute quantification assays were performed using a 7500 Sequence Detection 
System (Applied Biosystems). The thermal cycle included 10 minutes incubation at 
95 °C to activate polymerase, followed by a two-step amplification of 15s at 95 °C 
and 60 s at 57 °C for 40 cycles. Each experiment included non-template controls to 
exclude reagents contamination and serial diluitions of the specific synthetic 
template (Eurofin MWG Operon, Ebersberg, Germany). 
To obtain standard curves plasmids containing bacterial target sequences were 
used (Eurofin MWG Operon, Ebersberg Germany). The total amount was calculated 
by using the Thermo Scientific Nanodrop spectrophotometer. Standard curves were 
created with serial diluitions between 107 and 101 plasmids copies. 
The total quantification of absolute bacterial charges determined the relative 
amount of Helicobacter pylori. Under 10 U the results were considered as negative. 
Comparative statistics among the different groups was performed by using the IBM 
SPSS version 20.0, SPSS Inc, Chicago, IL, USA. 
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Informed Consent  
INFORMAZIONE AL PAZIENTE 
Correlazione tra salute parodontale e presenza di Helicobacter pylori all’interno de 
cavo orale. 
Gent.ma Signora, Gent.Signore 
Le viene chiesto di partecipare a uno studio clinico il cui obiettivo principale è quello di 
valutare la correlazione tra il suo stato di salute parodontale e la presenza all’interno 
della cavità orale del batterio Helicobacter pylori, causa principale dell’ulcera gastrica. 
Lo studio prevede l’accesso alla clinica Odontostomatologica di Velate (VA) dove verrà 
effettuata una prima visita di igiene orale, momento in cui verranno valutati gli indici 
parodontali iniziali. In maniera selettiva verranno utilizzati dei coni di carta per prelevare 
dei campioni biologici, i quali saranno analizzati successivamente attraverso il metodo 
della PCR (Polymerase Chain Reaction) per determinare o meno la presenza di 
Helicobacter pylori. 
Presso la clinica Odontostomatologica di Velate (VA), potrà essere inserito in un 
programma di prevenzione della salute orale. 
Le visite presso la clinica Odontostomatologica di Velate (VA) relative alla Sua 
partecipazione allo studio clinico sono gratuite e non prevedono alcuna spesa da parte 
Sua. 
La sua partecipazione è volontaria; per questo le verrà chiesto di firmare il modulo del 
consenso informato, il quale attesta la disponibilità a partecipare a questo studio. Tutte 
le informazioni raccolte durante lo studio saranno considerate strettamente 
confidenziali ed utilizzate soltanto ai fini dell’elaborazione statistica. 
Il suo nome sarà sostituito dalle iniziali e i dati personali saranno trattati in modo da 
mantenere un assoluto anonimato. 
In ogni caso, il trattamento dei dati avverrà nel rispetto di quanto previsto dalla 
normativa sulla privacy (196/2003). 
 
Fig. 30: an informed consent was filled in by patients before salivary and crevicular 
fluid examination 
  
 119 
 
        4.4    RESULTS 
A total number of 60 patients underwent the experimental procedure, 24 males and 
36 females. 
Among them, 30 tested positive for Breath test (group A) and 30 negative (group 
B). 
Age ranged between 16 and 78, with a mean age of 52,88 +/- 14,67. 
Among 24 male patients, 10 tested positive and 14 negative for Breath test, while 
among females 20 tested positive and 16 negative. 
Age ranged between 21 and 76 among negative patients (mean age 53,07 +/- 15,72) 
and between 16 and 78 among positive patients (mean age 52,7 +/- 13,81). 
 
 
Plot 12: males and female distribution among the two groups 
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Salivary samples values ranged from 0 to 103 units, with a mean value of 11,73 +/- 
20,08. 
Among them, 38 tested negative because they showed a value lower than 10 U, 
while 22 tested positive. 
 
 
Plot 13: 38 patients showed salivary HP units under 10 U, while 22 resulted as 
positive 
 
T-Student test for independent variables was used to compare the absolute values 
of HP detected in saliva within the two groups of positive and negative Breath test. 
The result was that there were not statistically significant differences (p=0,372). 
The Chi-square test was not statistically significant grouping saliva values into 
negative and positive groups (p=0,108). 
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Table 9: contingency table Breath test vs Saliva 
 Saliva Total 
Negative Positive 
Breath 
- 
Count 16 14 30 
Existimated 19,0 11,0 30,0 
+ 
Count 22 8 30 
Existimated 19,0 11,0 30,0 
Total 
Count 38 22 60 
Existimated 38,0 22,0 60,0 
 
T-Student test for independent variables was conducted for every quadrant in 
comparison with group variables of the Breath Test (group A vs group B). 
There was not any statistically significant difference as regards the presence of HP 
in saliva among the two groups of patients (p=0,604; p=0,326; p=0,368 and 
p=0,731). 
Afterwards, the statistical analysis focused on the presence of Helicobacter pylori in 
saliva and periodontal pockets following a new grouping based on the periodontal 
health conditions. 
The mean probing depth was calculated for every patient and a patient was 
considered to be healthy from a periodontal point of view when their mean probing 
depth was under 3, while he/she was to be affected by periodontal disease when 
his/her mean probing depth was >=3. 
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31 patients tested negative for periodontal disease (healthy), while on the contrary 
29 tested positive (unhealthy). This grouping procedure did not take into account 
the results from Breath Test. 
 
 
Plot 14: periodontal classification resulted in two homogeneous groups (negative 
and positive) in an independent pattern from CBT-U test 
 
The mean load of HP registered among the periodontally healthy patients 
(negative group) was 10,52 with SD 16,51, while it was 22,78 with SD 55,96 among 
affected patients (positive group). 
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Table 10: HP mean load in periodontally healthy vs affected patients.  
QM.caric =mean load; Qm.n=  probing depth 
 
 
The result was significant, demonstrating thus a correlation between periodontal 
disease (mean probing depth probing >= 3mm) and the presence of HP in 
periodontal tissues. 
 
Another statistical examination was conducted in order to verify if there was any 
difference within the group of periodontal patients subdivided into positive and 
negative to Breath test. 
There was not any statistical significant difference (p=0,305). 
The last analysis was conducted between periodontal patients and healthy patients 
as regards Helicobacter pylori’s load in the saliva. 
There was a significant difference between the two groups: periodontal patients 
showed an increased level of HP in saliva compared with healthy patients (Chi-
square p=0,05) 
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            4.5     DISCUSSION 
 
The current study represents a preliminary approach to the role of oral Helicobacter 
pylori (HP) in the relapses of gastric infection. 
60 patients were examined, subdivided into two groups of 30 individuals each 
according to the Breath test results: 30 were positive (group A) and 30 were 
negative (group B). 
Every patient underwent a thorough oral examination by a dental clinician. 
A paper cone was inserted for at least half a minute into the gingival sulcus near the 
dental element with the deepest probing depth. In addition, a salivary sample was 
collected with the spitting method. 
The PCR-RT technique allowed to evaluate the quantitative presence of HP in the 
oral cavity. 
Even though there was not any statistically significant difference among the two 
groups (A vs B) as regards the total amount of HP in saliva (t-Student p=0,372; chi-
square p=0,108) or in periodontal tissues (I quadrant p=0,604; II quadrant p=0,326; 
III quadrant p=0,368; IV quadrant p=0,731) it should be considered that Breath test 
and PCR-RT in oral cavity are two completely different methods of bacterial 
detection. 
The first one measures urease activity and distinguishes between positive and 
negative results, while the second one is quantitatively more accurate in detecting 
bacterial cells but requires a sample of liquid near the HP reservoir, a more invasive 
procedure for gastric mucosae since it needs esophagogastroduodenoscopy.  
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Besides, performing Breat test and PCR-RT for gastric and oral mucosa evaluation 
respectively does not allow to determine a causal factor, since these tests provide 
a picture of two anatomical districts at the same moment with two different 
methods. 
This was also confirmed by the comparison between group A and group B patients 
within the group of the only periodontal unhealthy patients (p=0,305). 
On the contrary, there was an interesting result as to the behaviour of HP in the oral 
cavity in relation to periodontal condition. 
Patients were subdivided into other two groups according to their periodontal 
health: if the mean probing depth was below 3 mm they were considered to be 
periodontal healthy, while if it was equal or greater than 3 mm they were classified 
as affected by periodontal disease. 
Comparing the mean amount of HP in periodontal pockets within the two groups, 
periodontal patients showed higher values, confirming that HP is present in the oral 
cavity and that it is not related to gastro-esophageal reflux or stomach load, like 
some authors have claimed, but it has an active role in the affected periodontal 
tissues. 
Periodontal disease represents a threatening disease for oral tissues, since it 
progressively destroyes the anchorage of dental elements to the alveolar bone 
through the formation of the so-called periodontal pockets, a reservoir of high dose 
of colonizing bacteria of different species, among which the most dangerous are 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella 
forsythensis, Treponema denticola, Fusobacterium nucleatum and Campylobacter 
rectus. 
Recent findings in the literature show how there is an immunological relationship 
between Helicobacter pylori and Campylobacter rectus [107], and clearly indicate 
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that one of the shared antigens is a GroEL protein; the biological activity of this 
protein might play a role in the onset and progression of periodontal disease. 
Furthermore, the microaerophilic and acid environment of the periodontal pocket 
represents a suitable context for growth and proliferation of Helicobacter pylori. 
Considering that Helicobacter was originally called Campylobacter-like bacterium, it 
could be advisable to consider it as a colonizing bacterium of the periodontal tissues 
when they are affected by the periodontal disease and when a biofilm with different 
species can increase the efficacy of the single species thanks to gene exchanges and 
signaling pathways among the different types of bacteria. 
HP in the periodontal tissues is not confined to periodontal pockets, but migrates 
from the gingival sulcus into saliva, as it was demonstrated by comparing the 
presence of the bacterium in the salivary fluid between periodontally healthy and 
unhealthy patients (p=0,05). 
Therefore, periodontal disease provides a suitable environment for HP. Periodontal 
pockets are the favourable site where the bacterium can thrive in synergy with 
other bacteria. Besides, once the bacterium has gained enough load, it migrates 
from the sulcus into the oral cavity and enters saliva. Since saliva is continuously 
swallowed and descends into the stomach, the oral cavity represents an extra-
gastric reservoir of Helicobacter pylori for the stomach. 
This preliminary study demonstrated that the oral cavity is an extra-gastric reservoir 
of Helicobacter pylori when it is affected by periodontal disease. The increased load 
of HP detected in periodontal disease is not confined to periodontal pockets, but 
the bacterium migrates from the gingival sulcus into the saliva and is transported to 
the stomach through swallowing. 
There is no statistical significance instead between the results of the Breath test and 
the PCR-RT carried out in the oral cavity, because they are two completely different 
methods with different sensibility and specificity and represent a picture at the 
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same moment of two different anatomical districts. However, it can be deduced 
that positivity for gastric infection is not linked to an increased amount of 
Helicobacter in the oral cavity. 
This preliminary study is undergoing a second step through a perspective study to 
better understand whether oral Helicobacter pylori can induce gastric infection 
relapses after eradication therapy. 
Patients who are negative for gastric infection and positive for oral infection will 
undergo evaluation through the Breath test and for oral infection with PCR-RT after 
6 months. If patients with a relapse are statistically associated to an increased oral 
Helicobacter pylori load when compared with a group of naive patients, it will be 
possible to establish the true role of the oral extra-gastric bacterium in gastric 
infection recurrence, which is a worldwide growing concern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 129 
 
5.    4th STUDY: RHEUMATOID ARTHRITIS THERAPIES AND 
PERIODONTAL DISEASE: ANY CORRELATION? 
 
       5.1   BACKGROUND 
 
Rheumatoid Arthritis (RA) is a systemic, chronic disease which has a multifactorial 
aetiology and an immunomediated pathogenesis. It affects several tissues and 
organs, such as the skin, blood vessels, heart, lungs and muscles, but joints are the 
mainly affected site. At this level the disease is associated with the onset of a non-
suppurative proliferative synovitis. Joints are typically affected bilaterally in a 
symmetric pattern. The disease, if untreated, leads to the destruction of joint 
cartilages, bone erosion and ankylosis [108]. 
 
5.1.1 History 
In 1800 Augustin Jacob Landré-Beauvais, in his doctoral dissertation, described the 
disease as a “primitive asthaenic gout” [109]. It was widespread especially among 
women, affected multiple joints, showed a chronic behaviour and led to joint 
stiffness and deformity. It should be considered that gout was the most common 
articular disease at that time, and that all other rheumoarthropaties were compared 
with this disease. 
Jean-Martin Charcot pointed out the typical night pain, the onset of the disease 
within the small distal joints and described the alternance of flare-up and remission 
periods. Finally, he called the disease “primary chronic rheumatism”. 
Sir Alfred Baring Garrod introduced the name of “Rheumatoid Arthritis” in 1859. 
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Disease prevalence in western countries has only recently risen, as described by 
paleoanthropological studies [110].  
 
5.1.2 Epidemiology 
About 1% of the worlwide population is affected by RA. 
Subsaharian and Caribbean black people appear to be less involved. The female to 
male ratio is 3:1, even though this difference is reduced among the elderly. 
The mean age ranges between 40 and 70 years, with two peaks in young adults and 
in pre-menopausal women [111]. 
 
5.1.3 Aetiology 
The disease is idiopathic. Rheumatoid Arthritis is a disease which can be explained 
by an autoimmune response after exposition to an unknown antigen in a genetically 
predisposed individual [112]. 
Mycoplasma, Epstein-Barr Virus, Cytomegalovirus, Parvovirus and Rubivirus have 
been taken into account, but the scientific literature is lacking in data. However, it 
seems that the molecular mimicry caused by infective agents could be the 
underlying cause of the disease, likewise in other autoimmune diseases. Therefore, 
HLA-DR4 or HLA-BDR1 haplotypes are associated with the disease [113]. 
 
5.1.4 Pathogenesis 
The autoimmune response, which leads to the activation of T-helper cells and other 
lymphocytes and the production of cytokines, destroys joint architecture. 
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The firts phase is characterized by the presence of monocytic-macrophagic cells just 
below the basal layer of the synovial membrane. At this time, IL-1, IL-6 and TNF 
cytokines are increased. 
Following activation of T-helper cells positive for CD154 leads to the polyclonal 
proliferation of B-lymphocytic cells and the production of autoantibodies. The 
increased production of cytokines and the recruitment of inflammatory cells is 
associated with an increased level of RANKL and osteoclastic activity [114]. Thus, 
bone resorption follows joint cartilage destruction. 
 
5.1.5 Clinical features 
The clinical course of the disease is variable. Over 50% of patients show an insidious 
and slow onset of the disease with malaise, fatigue, anorexia and diffused muscular 
pain before the involvement of joint cartilages [115]. These symptoms may lead to 
an early diagnosis. On the contrary, about 10% of patients show an acute onset with 
severe symptoms and the early involvement of multiple joints. In these cases, fever, 
lymphoadenophaty and splenomegaly accompain the clinical onset of the disease. 
RA usually involves the small distant joints most frequently those of the hands and 
feet, with a symmetrical pattern. 
Joints appear swollen and painful. Stiffness, especially in the morning, is evident. 
The clinical progress of the disease can be rapid or slow and patients usually go 
through alternate periods of partial/complete remission and of flare-up. Over time, 
this chronic condition leads to the impairment of function and deformity, especially 
of the hands [116]. 
Extra articular manifestations include several tissues and organs and are usually 
linked to the intensity of the disease activity [117]. 
 132 
 
 
- Rheumatoid nodules are asymptomatic lesions containing necrotic 
tissue and macrophagic infiltration. They are usually found in 
periarticular structures or in those areas which undergo mechanical 
pressure, sometimes in pleura and meninges. 
 
- Rheumatoid vasculitis is associated with an increased level of 
circulating Rheumatoid Factor. It can develop anywhere and result in 
polyneuropathies, cutaneous ulcers, visceral infections and finger 
canker. 
 
- Pleuropulmonary manifestations include pleuritis, interstitial fibrosis 
and nodules. They are more frequent in males. 
 
- Neurological symptoms are related to the entrapment of nerve 
trunks within the tissutal destruction around joints, especially in 
hands and in vertebral column due to subluxation. 
              Ulnar, median and anterior tibial nerves are those generally involved. 
 
- Ocular signs usually include episcleritis and scleritis, even though 
they usually affect less than 1% of individuals. 
 
- Oral symptoms and signs are xerostomia, Temporo-Mandibular Joint 
dysfuntion, ulcers due to the administration of metothrexate, 
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increased predisposition to periodontal disease. Sometimes Sjögren’s 
Syndrome is associated to Rheumatoid Arthritis. 
 
- Felty’s syndrome is a form of chronic RA accompanied by 
splenomegaly, neutropenia, anaemia and thrombocytopenia 
sometimes. It usually arises in individuals with long-lasting disease 
and leads to an increased susceptibility to infections. 
 
- Osteoporosis is frequent and is mainly due to the prolonged steroid 
therapy. 
 
- Lymphoma, mainly the large cell B lymphoma, is more frequent in 
patients with Rheumatoid Arthritis, when the polyclonal proliferation 
degenerates into a monoclonal one. 
 
5.1.6 Risk Factors 
Several studies suggest the presence of intrafamiliar genetic predisposition, 
especially within direct line [118]. Over 70% of patients are positive for HLA-DR4 
[119], while others show alterations within the genes for cytokines and TNF. 
Among cytokines, Interleukine-6 plays an important role, since an uncontrolled 
overproduction may lead to the onset of severe chronic disease with autoimmune 
response. Some papers showed that the use of a monoclonal antibody directed 
against IL-6 receptor is effective in the treatment of RA. 
Vitamin D receptor gene is also involved, especially as regards accompanying 
osteoporosis and pathological fractures [120]. 
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Among enviromental factors smoke is considered the most influencing one in the 
epidemiology of Rheumatoid Arthritis. 
 
5.1.7  Diagnosis 
There is usually a delay of 9 months between the onset of the first symptoms and 
final diagnosis. This occurs because of the non specificity of early complaints. When 
the inflammatory involvement of joints concerns the small and distal joints 
bilaterally and the vertebral column is not affected, a strong suspicion of RA can 
arise. 
Stiffness in the morning and chronic fatigue, accompanied by the presence of 
subcutaneous nodules, are characterizing features of the disease. 
In 1987 the American College of Rheumatology developed Revised Criteria for the 
classification of Rheumatoid Arthritis [121]. 
These criteria provide a sensibility rate of 94% and a specificity rate of 89%. The final 
diagnosis is made considering clinical features, radiographic imaging, blood 
chemistry and synovial liquid examination. 
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Fig.31: Revised Criteria for the Classification of Rheumatoid Arthritis 
 
Serum values are important indicators for disease activity and appear as prognostic 
elements to distinguish between aggressive and non-aggressive forms and to 
determine the response to treatment.  
- High levels of ESR and CRP indicate the presence of imflammation. 
CRP, especially, is connected with disease severity and appearance of 
lesions [122]. 
- Rheumatoid Factor (RF) is an autoantibody directed against the Fc 
portion of IgG antibodies and is expressed in 60-70% of patients with 
RA. It is not a highly specific antibody, since it can also be found in 
Cryoglobulinemia, Sjögren’s Syndrome, chronic hepatopathies. 
However, it is a valuable prognostic factor, since it is high when RA 
appears aggressive and with an erosive clinical evolution. 
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- Anti-citrullinated protein antibodies (CCP), on the contrary, are 
highly specific and sensible. They are characteristically epressed in 
Rheumatoid Arthritis, so their value is both diagnostic and prognostic 
[123]. 
The synovial liquid examination is a routine test which is performed to distinguish 
between inflammatory and mechanical arthtritis or between infective or 
microcrystal arthritis. 
Traditional radiographic imaging is still the gold-standard test to evaluate the joint 
damage over time and also appraise damage to bones due to erosion. 
Ecography could be performed to obtain a dynamic evaluation of the joint function, 
but it is still too much influenced by the operator’s skills. 
Magnetic Resonance, instead, is homogeneous and can be read by different 
operators, but it is expensive and less accessible. 
In 1970 the epidemiologist Alvam Feinstein introduced the term “Clinicometrics” to 
better standardize the clinical evolution of symptoms and signs in a chronic disease. 
The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). DAS stands 
for 'Disease Activity Score' and the number 28 refers to the 28 joints examined in 
this assessment [124].  
 There is a wide range of measures to assess disease activity in RA including:  
• examination of joints for swelling and tenderness, 
• global scores of pain and overall status, 
• blood markers of inflammation (e.g. ESR and CRP),  
• questionnaires (e.g. the HAQ), 
• X-rays, and newer imaging techniques such as ultrasound and MRI.  
The DAS28 is a composite score derived from 4 of these measures. This ‘28’ version 
is a simplification of the original DAS score, which required 44 joints to be counted. 
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Other versions of DAS28 allow CRP to be used instead of ESR, or the omission of 
either. To calculate DAS28 the rheumatologist or a specialist nurse:  
1 counts the number of swollen joints (out of the 28), 
2 counts the number of tender joints (out of the 28), 
3 takes blood to measure ESR or CRP, 
4 asks the patient to make a ‘global assessment of health' (indicated by marking a 
10 cm line between very good and very bad).  
These results are then fed into a complex mathematical formula to produce the 
overall disease activity score. A DAS28 of more than 3.2 implies active disease, less 
than 3.2 low disease activity, and less than 2.6 remission. 
 
Fig.32: DAS-28 score system to assess Rheumatoid Arthritis clinical activity 
 
Extra articular manifestations are taken into consideration as prognostic factors of 
disease severity. 
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5.1.8 Therapy 
Therapy requires a multidisplinar approach which involves the rheumatologist, the 
physiatrist, the orthopedist, the psycologist and the dentist. After making a 
diagnosis and assessing disease activity the choice of treatment must be patient-
tailored. 
Drugs are commonly used as palliative therapy in order to keep the inflammation 
scores at low levels [125]. 
NSAIDs are commonly used to treat pain or acute inflammation, while steroids are 
used to control inflammation, even though they seem to be linked to a delay in bony 
erosion onset. 
However, NSAIDs and steroids are not capable of delaying disease progression. 
Disease Modifying Anti-Rheumatic DRUGS (DMARDs) are a class of drugs which 
reduce the level of reactants in the acute phase and modulate the inflammatory 
components of the disease. They have a beneficial effect only after several weeks 
or months. Gold compounds, antimalarials, sulfalazine, penicillamine and expecially 
metothrexate belong to this group. 
Methotrexate is a folic acid antagonist, it hinders the nucleic acids synthesis and 
stops the proliferation of several cell types, among which the inflammatory cells. 
Adverse effects include leukopenia, thrombocytopenia, anaemia, haemorrhages, 
myelosuppression, gastroenteric ulcers, stomatitis, dyarrhea. 
Biological drugs are inhibitors of cytokines production. They usually are antibodies 
directed against a molecule or a receptor and are characteristically associated with 
less side effects since they aim at more specific targets. They are usually composed 
of big-sized molecules and can’t be administered per os.  Etanercept, infliximab, 
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adalimumab are the most used drugs. Etanercept is a biopharmaceutical that treats 
autoimmune diseases by interfering with Tumor Necrosis Factor (TNF; a soluble 
inflammatory cytokine) by acting as a TNF inhibitor. 
It reduces the effect of naturally present TNF, functioning as a decoy receptor that 
binds to TNF [126]. 
Tumor Necrosis Factor-alpha (TNF-α) is a cytokine produced by lymphocytes and 
macrophages, two types of white blood cells. It mediates the immune response by 
attracting additional white blood cells to sites of inflammation, and through 
additional molecular mechanisms which initiate and amplify inflammation. 
Inhibition of its action by Etanercept reduces the inflammatory response which is 
especially useful for treating autoimmune diseases. 
There are two types of TNF receptors: those found embedded in white blood cells 
that respond to TNF by releasing other cytokines, and soluble TNF receptors which 
are used to deactivate TNF and blunt the immune response. In addition, TNF 
receptors are found on the surface of virtually all nucleated cells. Etanercept mimics 
the inhibitory effects of naturally occurring soluble TNF receptors, the difference 
being that etanercept, because it is a fusion protein rather than a simple TNF 
receptor, has a greatly extended half-life in the bloodstream, and therefore a more 
profound and long-lasting biologic effect than a naturally occurring soluble TNF 
receptor. 
Immunosuppressants and cytotoxic drugs are used when DMARDs or 
biopharmaceuticals fail in the treatment of RA. Chloroquine, hydroxychloroquine, 
cyclosporine, azathioprine and cyclophosphamyde belong to this group. 
Folic acid is frequenty prescribed to hinder the low absorption of the element due 
the intake of metothrexate, while vitamin D is given to reinforce bones and because 
a high index of bone resorption is associated with greater disease severity. 
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Patients with Rheumatoid Arthritis need following for physical exercise in order to 
move the affected Joints without increasing the inflammatory indices. 
Surgery, such as athroplasty or joint substitution, is performed, while synevectomy 
does not seem to produce long-lasting results. 
 
5.1.9 Periodontal Disease 
With tooth decay Periodontal disease (PD) is one of the two most common diseases 
of the oral cavity. It affects about 80% of the world population. The disease involves 
the supporting periodontal tissues which include the gums, periodontal ligament 
and alveolar bone.  The final evolution of the disease is the loss by exfoliation of 
dental elements. Genetic predisposition may play an important role in determining 
whether an individual can be affected, but dental plaque is the causal agent. 
Periodontal disease may have several clinical forms, but chronic periodontitis is the 
most widespread among adults. It can affect individuals of any age, but prevalence 
increases with age. It can be confined to a single group of teeth or affect the entire 
mouth [127]. 
Sick gingiva appears as erythematous, edematous and painful; the presence of 
periodontal pockets represents a reservoir of infection which leads to dental 
mobility and loss. Gingival recession, furcation exposure in the oral cavity and dental 
migration may also occur as a consequence of the loss of periodontal attachment 
loss. 
Gingivitis is the initial form of the disease; it represents a reversible stage in which 
tissue destruction does not occur yet. Some cases of gingivitis can advance to a 
more severe condition, periodontitis. Periodontitis is the non-reversible destruction 
of periodontal ligament and alveolar bone and is always preceeded by gingivitis. 
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The worsening of the condition or its clinical course depend on the host immunitary 
defenses. 
Chronic periodontitis may only affect a localized region or the whole mouth. 
The prerequisite for the onset of the disease is the presence of a supragingival and 
then subgingival bacterial biofilm around the dental element and inside the gingival 
sulcus. 
Risk factors may worsen the course of the disease. These factors are occlusal 
trauma, bad habits, oral respiration, atypical deglutition, poor hygienic oral 
conditions, dental malposition, dental abnormalities, low adherent gingiva, ill-fitting 
dental restorations, orthodontic appliances, smoke, systemic diseases, drugs [128]. 
From 1890 to 1930s periodontitis was believed to be a specific infection caused by 
fusiform bacteria, amoebas, spirochetes and streptococci. 
From 1930 to the end of 1960s periodontitis was held to be a non-specific infection 
caused by the presence of dental plaque. From 1960 the theory of specific 
organisms responsible for the disease has drawn the attention of scientists and 
several bacterial species as potentially causal agents have been investigated. 
It should be underlined that dental plaque contains more than 300 different 
bacterial species, but only a few have been associated with a high risk of developing 
periodontal disease. 
The link between biofilm bacteria and periodontitis is not random. Six species have 
been found to be strictly involved and responsible for the clinical course of the 
disease: Aggregatibacter actinomycetemcomitans, Porhyromonas gingivalis [129], 
Tannerella forsythensis, Treponema denticola which belong to the so-called “red-
complex” and Fusobacterium nucleatum and Campylobacter rectus, which belong 
to the “orange-complex”.  
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Fig. 33: microbial complexes in subgingival biofilm 
 
However, bacterial infection is a necessary factor but it is not sufficient for the onset 
of the disease, since host immunologic status and local environment are important 
too. 
Dental plaque accumulation triggers a reaction in the junctional epithelium and 
epithelial sulcus, which produce proinflammatory cytokines and inflammation 
mediators. Gingivitis follows the inflammatory response, with oedema and PMN 
migration in the sulcus due to the chemotactic gradient. PMN accumulation and 
degradation within the sulcus results in tissue damage and epithelial regeneration 
which migrates apically with consequent bony loss. 
Diagnosis requires clinical, instrumental and radiographic evaluation. 
Clinical and instrumental criteria are bleeding on probing, depth probing, clinical 
attachment level, furcation involvement, teeth looseness. 
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The different parameters are grouped into several recognized indices which can 
determine the presence or absence of periodontal disease. 
Once a thorough periodontal examination and diagnosis have been performed, 
aetiological therapy is imperative. 
Firstly, professional dental cleaning (scaling) removes dental plaque from the tooth-
sites and gingival sulcus. 
Afterwards, when periodontal pockets are present, debridement of subgingival 
plaque is performed through curettage, known as root planing. 
If aetiological therapy is not sufficient, the dental clinician can remove infection 
surgically from those areas too deep to be reached during root planing procedures. 
Chlorexidine digluconate 0,2% mouth rinses can improve the efficacy of aetiological 
therapy, but they can’t be used for more than two weeks. 
 
5.1.10 Genetic predisposition to Periodontal Disease 
The hypothesis of a genetic predisposition in Periodontal Disease was firstly 
formulated in 1935. 
The discovery that genetics influences the development of Periodontal Disease 
dates back to 30 years ago [130]. This new evidence has shown that PD, like other 
diseases (diabetes, cancer, etc.), requires a genetic susceptibility to develop. 
Individuals respond differently to the attack of the oral microflora according to their 
genetic predisposition. Furthermore, genetics determines how each person 
interacts with environmental factors (such as oral biofilm) in the onset of PD. The 
relationship between genetic and environmental factors determines the onset of 
PD. Lifestyle (smoke and poor oral hygiene) affects the onset and progression of PD, 
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but alone it is not ablo to cause it [131]. The probability of developing PD related to 
heredity is about 50%. Clinical studies have shown that genetic factors are jointly 
responsible with environmental factors and lifestyles for the development of PD 
[132]. 
Genetic susceptibility to multifactorial diseases is usually due to several gene 
polymorphism instead of a single, or few, gene mutations. Common variation in the 
genetic code may result in an altered expression or in functional changes of the 
encoded proteins, therefore in an increased disease severity.  
Recently, research into susceptibility factors of periodontitis has mainly focused on 
genes that modulate immune regulation, such as cytokines, chemokines, cell-
surface receptors, enzymes and proteins related to antigen recognition. Cytokines, 
such as IL-1α, IL-1ß, IL-10 and IL-6, are key factors which mediate the inflammatory 
process during periodontitis progression. They have a role in activation, 
proliferation and differentiation of B cells which are the majority of infiltrating cells 
in advanced periodontitis lesions. Therefore, common variations in the genetic code 
can alter the progression of disease because they may be responsible for the 
repeated cycles of tissue inflammation [133]. 
In Periodontal Disease, the microbiota accumulated in the subgingival region is the 
environmental factor which influences the inflammatory response in periodontal 
tissues. However, cytokines contribute to connective tissue destruction and bone 
resorption.  
Another factor associated with bone resorption in periodontal disease is Vitamin D 
Receptor (VDR), which has been regarded as a periodontitis susceptibility factor. 
Recent articles have reported a review of scientific literature as to the genetic 
association analysis between common polymorphism of candidate genes and 
periodontitis [134]. Vitamin D Receptor expression may be linked to bone pathology 
following periodontal destruction. 
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Interleukin-1 genes (IL-1) are pro-inflammatory agents, since IL-1 is associated with 
inflammation, bone resorption. TNF-α is also linked to an increased degree of 
inflammation within periodontal tissues. IL-1 and TNF-α are also associated with 
Rheumatoid Arthritis, thus these two diseases can be linked on the basis of the role 
played by pro-inflammatory cytokines could be formulated. 
IL-10 is considered to be an antinflammatory cytokine which modulates the activity 
of IL-1 and TNF-α. 
A recent paper has underlined the presence of Interleukin-6 gene methylation both 
in Rheumtoid Arthritis and Periodontal Disease [135]. 
 
     5.2    AIM 
The current study aims at evaluating the correlation between Rhematoid Arthritis 
(RA), with special attention to therapy, and Periodontal Disease (PD).  
 
 
     5.3    MATERIALS AND METHODS 
34 patients with Rheumatoid Arthritis were recruited into the current study. 
The study was conducted in the Unit of Rheumatology, Ospedale di Gallarate, VA, 
Italy. 
Patients were subdivided into three groups: Group 1 included 13 patients treated 
with TNF-α biological inhibitors (Etanercept), Group 2 included 14 patients treated 
with Methotrexate and 7 patients were included in Group 3 as control subjects. The 
control group consisted of patients affected by Rheumatoid Arthritis but not treated 
with any drug. 
 146 
 
Exclusion criteria concerned patients who were partially or completely edentulous. 
The experimental protocol has been evaluated by the Institutional review Board, 
reference number 127/2016. 
The rheumatologist collected data about disease severity and laboratory findings. 
Among haematochemical analysis, Rheumatoid Factor (RF), anti-citrullinated 
protein antibody (CCP) and HLA-BDR1 were prescribed. The DAS28 questionnaire 
was completed by the physician in order to measure the clinical scores of disease 
activity. 
A dental clinician carried out a periodontal examination, collecting data from 
periodontal probing with special attention to Depth probing. 
Afterwards, 1 paper cone was inserted for 30 seconds into the gingival sulcus near 
the dental element with the deepest probing value registered for every quadrant 
and then sent to the laboratory for evaluation in a sterile test tube. 
Specimens were processed to extract and purify DNA by using a method that 
includes two consecutive incubations with lysozyme and proteinase K, in order to 
ensure an indiscriminate Gram positive and negative bacterial lysis. Once extracted, 
DNA was purified through a silica spin-column (Sigma-Aldrich, St. Louis, MO, USA). 
Quantitative PCR of 16S rRNA genes was performed with the hydrolysis probes 
method to identify and evaluate the amount of 5 bacterial species: Porphyromonas 
gingivalis, Tannerella forsythensis, Treponema denticola, Fusobacterium nucleatum 
and Campylobacter rectus. 
The 845 sequences of 16S rRNA gene of the Human Oral Microbiome Database 
(HOMD 16S rRNA RefSeq Version 10.1) were aligned to find either a consensus 
sequence or less preserved spots, useful to optimize the specificity of primers and 
dual labelled hydrolysis probes. PCR oligonucleotide sequences were designed by 
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Primer3web (http://primer3.ut.ee/) and Primer Express (Life Technologies) 
software. The specificity of PCR assays was also checked by Primer-Blast 
(http://www.ncbi.nlm.gov/tools/primer-blast/). Absolute quantification assays 
were performed by using a 7500 Sequence detection System (Applied Biosystems). 
The thermal cycle included 10 min incubation at 95°C to activate polymerase, 
followed by a two-step amplification of 15 s at 95°C and 60 s at 57°C for 40 cycles. 
Each experiment included non-template controls to exclude reagents 
contamination and serial diluitions of the specific synthetic template (Eurofin MWG 
Operon, Ebersberg Germany). These positive controls were used to plot standard 
curves, i.e threshold cycle values against the log of the copy number, that were used 
either to check amplification efficiency and for quantification of targets in each 
sample. 
Data from quantitative PCR included the amount of each of the 5 investigated 
bacterial species and a measurement of the bacterial load from up to 34 patients. 
These amounts matched the number of DNA molecules detected in the real time 
PCR tubes that was directly related to the number of bacteria in the specimens. In 
order to enhance data analysis with noise removal, statistical analysis was 
performed on relative amounts, calculated as ratios between the amount of each 
species and the total bacterial load. This was able to reduce variability due to 
random factors such as specimen conservation, DNA extraction efficiency, and 
purification yield, as well as variability due to systematic factors, for instance the 
higher amount of bacteria expected in specimens from deeper pockets 
characterizing periodontitis. 
Samples for periodontal tissues were also used to assess genetic polymorphism in 
IL-6, IL-10 and VDR [136]. 
Comparative statistics among the different groups was performed using the IBM 
SPSS version 20.0, SPSS Inc, Chicago, IL, USA. 
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5.4   RESULTS 
A total number of 34 patients affected by Rheumatoid Arthritis were recruited in 
the current study, 24 females and 10 males. 13 patients were undergoing therapy 
with Etanercept, an anti TNF-α biopharmaceutical; 14 patients were undergoing 
therapy with Methotrexate, an immunosuppressant, and 7 did not follow any 
therapeutic regimen (Control group). 
 
Plot 15: sex distribution among the 34 recruited patients 
 
Plot 16: composition of Group 1 (Etanercept), Group 2 (Methotrexate) and Group 
3 (Control) 
Sex distribution
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Firstly, comparative analysis was performed to verify any correlation between 
genetic predisposition to Periodontal Disease and Rheumatoid Arthritis laboratory 
findings, both clinical and genetic. 
IL-6 was regarded as predisposing to Periodontal Disease when genotype GG of the 
polymorphism rs1800795 (G/C) was expressed, while genotypes GC and CC were 
considered to be protective against Periodontal Disease. 
3 patients expressed the protecting genotype, while 31 expressed the predisposing 
one. 
IL-10 was considered predisposing to Periodontal Disease when genotypes AA and 
AC of the polymorhism rs1800872 (A/C) were expressed, while genotype CC was 
considered to be protective against the disease.  
12 patients expressed the protecting genotype, while 22 expressed the predisposing 
one. 
VDR was considered as predisposing to Periodontal Disease when genotype TC of 
the polymorphism rs731236 (T/C) was expressed, while genotypes TC and CC were 
considered protective against the disease. 
 
Table 11: cytokines genotypes resulting from crevicular fluid analysis 
 PREDISPOSING PROTECTING 
INTERLEUKIN-6 GENOTYPE 31 3 
INTERLEUKIN-10 GENOTYPE 22 12 
VIT D RECEPTOR GENOTYPE 28 6 
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Rheumatoid Factor (RF) was positive in 21 patients and negative in 13 ones. 
Anti-citrullinated protein antibody (CCP) was positive in 19 patients and negative in 
15 patients. 
DAS-28 ruled out 17 patients with a score of 1 (x< 2,6), 9 with a score of 2 (2,6<x<3,2) 
and 8 with a score of 3 (x>3,2); class 2 and 3 were united in a unique class so that 
the division was between 17 patients with absent disease activity and 17 with 
higher scores of disease.  
HLA-BDR1 was registered in 10 patients while it did not appear in the remaining 24. 
 
Table 12: rheumatic parameters collected from blood examination and DAS-28  
 RF CCP DAS-28 HLA-BDR1 
POSITIVE 21 19 17 10 
NEGATIVE 13 15 17 24 
 
Non-parametric Chi-square analysis was performed to compare predisposing and 
protecting genotypes of Interleukin-6 (IL-6) with Rheumatoid Factor (RF), anti-
citrullinated protein antibody (CCP), clinical assessment of Rheumatoid Arthritis 
DAS-28 and HLA-BDR1 haplotype. 
There was not any statistically significant difference when IL-6 was compared with 
RF, CCP and HLA-BDR1, even though it should be considered that most patients 
expressed a predisposing genotype and the two groups were not balanced. 
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-  IL-6 vs RF p=0,22; 
-  IL-6 vs CCP p=0,16;  
-  IL-6 vs DAS-28 p=0,11;  
-  IL-6 vs HLA-BDR1 p=0,66. 
The same analysis was performed to compare genotypes of Interleukin-10 (IL-10) 
with Rheumatic parameters. 
There was not any significant difference between 
- IL-10 vs RF p=0,06 
- IL-10 vs DAS-28 p=0,36 
- IL-10 vs HLA-BDR1 p=0,22 
On the contrary, it seems that IL-10 and CCP are associated in an opposite pattern: 
when IL-10 expresses protecting genotypes against periodontitis, CCP may be 
increased, while when predisposing genotypes are expressed, CCP is decreased. 
IL-10 vs CCP p=0,02 
 
Table 13:  contingency table IL10 vs CCP 
 CCP Total 
Negative Positive 
IL10 Protecting 2 10 12 
Predisposing 13 9 22 
Total 15 19 34 
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VDR results were compared with those of RF, CCP, DAS-28 and HLA-BDR1. 
There was not any significant difference in the Chi-square analysis. 
- VDR vs RF p=0,24 
- VDR vs CCP p=0,45 
- VDR vs DAS-28 p=0,33 
- VDR vs HLA p=0,42 
 
Table 14: results from comparative statistical analyses are reported. A significant 
connection was found between IL-10 and CCP 
 RF CCP DAS-28 HLA-BDR1 
IL-6 0,22 0,16 0,11 0,66 
IL-10 0,06 0,02 0,36 0,22 
VDR 0,24 0,45 0,33 0,42 
 
Non-parametric statistical analysis was performed to compare periodontal genetic 
indices among them.  
 
- IL-6 vs VDR p=0,07 
- IL-10 vs VDR p=0,35 
 
There were not differences with the exception of IL-6 vs IL-10, which turned out 
significative (p=0,014). When the individual is genetically predisposed to 
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periodontal disease in IL-6 genes, also IL-10 seem to be correlated and both 
cytokines express predisposing genes. 
 
Table 15: contingency table IL6 * IL10 
Count 
 IL10 Total 
Protecting Predisposing 
IL6 
Prot 3 0 3 
Pred 9 22 31 
Total 12 22 34 
    
 
 
Table 16: comparative analysis limited to genetic periodontal indices. A significant 
correlation was found between IL-6 and IL-10 
 IL-6 IL-10 VDR 
IL-6 Not applicable 0,014 0,07 
IL-10 0,014 Not applicable  
VDR 0,07 0,35 Not applicable 
 
Comparing Rheumatic factors among them showed strict correlations within the 
population, according to data from the international literature. 
 154 
 
 
- RF vs CCP p=0,00 
- RF vs DAS-28 p=0,14 
- RF vs HLA p=0,00 
- CCP vs DAS-28 p=0,04 
- CCP vs HLA p=0,00 
- DAS-28 vs HLA p=0,74 
 
DAS-28 is a parameter which results from both laboratory findings and clinical 
evaluation of the disease. Thus it is less associated with rheumatic factors than the 
others do. 
Rheumatoid Factor and HLA-BDR1, in particular, do not show significant differences 
when compared to DAS-28. 
 
Table 17: comparative analyses limited to rheumatic parameters 
 RF CCP DAS-28 HLA 
RF Not applicable 0,00 0,14 0,00 
CCP 0,00 Not applicable 0,04 0,00 
DAS-28 0,14 0,04 Not applicable 0,74 
HLA 0,00 0,00 0,74 Not applicable 
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CCP appears as the only rheumatoid arthritis parameter which is more associated 
to other factors.  
Sex was compared to periodontal genetic predisposition and rheumatic 
parameters. 
IL-10 predisposing gene is expressed more in males than females (p=0,05) 
Sex vs IL-6 p=0,34 
Sex vs IL-10 p=0,046 
Sex vs VDR p=0,58 
 
Table 18: contingency table SEX vs IL-10 
Count 
 IL10 Total 
Protecting Predisposing 
Sex 
F 11 13 24 
M 1 9 10 
Total 12 22 34 
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In addition, Rheumatoid Factor is more common among females than males. 
Sex vs RF p=0,02 
Sex vs CCP p=0,056 
Sex vs DAS-28 p=0,75 
Sex vs HLA-BDR1 p=0,12 
 
Table 19: comparative analyses between sex on one side and periodontal and 
rheumatic parameters on the other side 
 IL-6 IL-10 VDR RF CCP DAS-28 HLA 
SEX 0,34 0,05 0,58 0,02 0,056 0,75 0,12 
 
Microbiological analysis was performed comparing the mean load of every 
bacterium with PSR and with Rheumatoid Arthritis parameters using the T-student 
parametric test for independent values. 
Periodontal screening record (PSR) index was calculated for every patient. PSR is a 
clinical parameter which allows to distinguish between the presence and absence 
of periodontitis and its clinical severity. 22 patients show a PSR score below 3, while 
on the contrary 12 reported a PSR greater than 3.  
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Plot 17: 22 patients reported a PSR score <=3, while 12 showed a PSR score >3 
 
Porphyromonas gingivalis (PG), Tannerella forsythensis (TF), Treponema denticola 
(TD), Fusobacterium nucleatum (FN) and Campylobacter rectus (CR) mean loads 
were compared to the groups of patients individuated after PSR. 
 
- PG vs PSR p=0,09 
- TF vs PSR 0,88 
- TD vs PSR p=0,25 
- FN vs PSR p=0,241 
- CR vs PSR p=0,41 
There were not any statistical difference in the composition of oral microbioma 
between the two groups, being the bacterial infection influenced by other factors 
and not by clinical scoring of periodontal disease. 
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Afterwards, bacterial mean loads were compared with Rheumatic parameters to 
check whether Rheumatoid disease itself or the activity of the disease may 
represent a risk factor of aggressive pathogens in periodontitis. 
Rheumatoid Factor showed a positive correlation with the presence of Tannerella 
forsythensis and Treponema denticola, but not with Porphyromonas gingivalis, 
Fusobacterium nucleatum or Campylobacter rectus. 
 
Table 20: descriptive statistics RFvsTF 
 
RF N Mean St deviation St error 
mean 
TFMEAN 
NEG 13 3001,5385 4786,34485 1327,49 
POS 21 7929,9286 12468,76229 2720,91 
 
 
Table 21: descriptive statistics RFvsTD 
 
RF N Mean St deviation St error 
mean 
TDMEAN 
NEG 13 8635,0000 11811,0645 3275,80 
POS 21 37832,0476 79611,7628 17372,71 
 
There was a significant link between the anti-citrullinated protein antibody (CCP) 
and the presence of the red-complex bacteria: Porphyromonas gingivalis, 
Tannerella forsythensis and Treponema denticola. On the contrary, there was not 
relationship with the orange-complex bacteria Fusobacterium nucleatum and 
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Campylobacter rectus. 
 
Table 22: descriptive statistics CCPvsPG 
 
CCP N Mean St deviation St error 
mean 
PGMEAN 
NEG 15 29131,03 55816,035 14411,64 
POS 19 166058,24 410745,594 94231,50 
 
Table 23: descriptive statistics CCPvsTF 
 
CCP N Mean St deviation St error 
mean 
TFMEAN 
 NEG 15 2618,93 4545,14 1173,55 
 POS 19 8750,77 12855,93 2949,35 
 
Table 24: descriptive statistics CCPvsTD 
 
CCP N Mean St deviation St error 
mean 
TDMEAN 
NEG 15 7718,87 11217,22 2896,27 
POS 19 41628,69 82958,91 19032,08 
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DAS-28 revealed a positive relationship with the presence of all bacteria of the red 
and orange complexes 
- DAS-28 vs PG p=0,01 
- DAS-28 vs TF p=0,02 
- DAS-28 vs TD p=0,04 
- DAS-28 vs FN p=0,01 
- DAS-28 vs CR p=0,01 
On the contrary, HLA-BDR1 Genetic predisposition to Rheumatoid Arthritis is not 
linked to the presence of aggressive periodontal bacteria. 
- HLA vs PG p=0,73 
- HLA vs TF p=0,91 
- HLA vs TD p=0,64 
- HLA vs FN p=0,48 
- HLA vs CR 0,45 
-  
Table 25: summary of statistical analysis between rheumatic 
parameters and periodontal pathogens 
 PG TF TD FN CR 
RF 0,07 0,04 0,04 0,94 0,27 
CCP 0,04 0,01 0,02 0,82 0,17 
DAS-28 0,01 0,02 0,04 0,01 0,01 
HLA-BDR1 0,73 0,91 0,64 0,48 0,45 
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Patients were finally analyzed on the basis of the therapeutic protocol they were 
following. 
Group 1 was under treatment with Etanercept 
Group 2 was under treatment with Methotrexate 
Group 3 was not under any treatment 
 
- PG in groups 1,2,3 (ANOVA one way) p=0,28 
- PG in groups 1,2 p=0,02 
- PG in groups 2,3 p=p,07 
- TF in groups 1,2,3 p=0,08 
- TF in groups 1,2 p=0,00 
- TF in groups 2,3 p=0,03 
- TD in groups 1,2,3 p=0,20 
- TD in groups 1,2 p=0,01 
- TD in groups 2,3 p=0,06 
- FN in groups 1,2,3 p=0,35 
- FN in groups 1,2 p=0,85 
- FN in groups 2,3 p=0,07 
- CR in groups 1,2,3 p=0,21 
- CR in groups 1,2 p=0,06 
- CR in groups 2,3 p=0,09 
 
Statistical differences were registered among patients undergoing therapy with 
Etanercept (group 1) and those undergoing treatment with Methotrexate (group 2) 
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in the mean load of bacteria belonging to the red complex, while there were no 
differences of bacteria belonging to the orange complex. 
 
Table 26: summary of statistical analyses between therapeutic regimens 
(Etanercept-Methotrexate) and periodontal pathogens 
 PG TF TD FN CR 
Total 0,28 0,08 0,20 0,35 0,21 
Et vs Met 0,02 0,00 0,01 0,85 0,06 
Met vs Ctrl 0,07 0,03 0,06 0,07 0,09 
 
The control group appeared as a disturbing factor in the overall statistic, since it 
masked the effect of a therapeutic regimen on the composition of oral microbioma 
compared to an other treatment. 
Patients undergoing therapy with Methotrexate reported higher levels of bacteria 
belonging to the red group. 
Conversely, bacteria belonging to the orange groups were not influenced by the 
therapeutic regimen. 
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    5.5   DISCUSSION 
Rheumatoid Arthritis (RA) is a systemic, chronic disease which is characterized by a 
multifactorial aetiology and an immunomediated pathogenesis. About 1% of the 
world population is affected, expecially women aged between 40 and 70 years. 
Even though the disease is idiopathic, since it is an autoimmune response without 
an apparent causal agent, recent findings in the literature have tried to explain how 
genetic predisposition and environmental factors may play a role in the 
maintenance of chronic inflammation in the joints and other organs. 
The oral cavity represents a reservoir of more than 300 bacterial species which 
colonize gingival and periodontal tissues leading to a chronic inflammatory state, 
where bacterial virulence is thwarted by host immunologic defenses. 
The chronic stimulation of the immune system due to the presence of bacterial 
antigens within periodontal tissues has been associated with several systemic 
autoimmune diseases, like diabetes mellitus or other pathologies, infective 
endocarditis or cardiovascular atherosclerosis. 
Rheumatoid Arthritis and Periodontal Disease (PD) share some common features, 
in particular many of the cytokines which maintain inflammation (i.e. IL-6, IL-10, 
TNF-α). 
The current study suggestes that in a group of patients affected by Rheumatoid 
Arthritis parameters with periodontal genetic risk factors be compared with the 
microbiological composition of the bacterial load. 
Among rheumatic parameters Rheumatoid Factor (RF), anti-citrullinated protein’s 
antibody (CCP) and HLA-BDR1 were collected by blood samples, while DAS-28 
questionnaire was fulfilled by the rheumatologist in order to establish a recognized 
score of the disease activity.  
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Genetic predisposition to Periodontal disease is mainly due to the presence of 
several polymorphisms of the genes expressing Interleukin-6 (IL-6), Interleukin-10 
(IL-10) and Vitamin D Receptor (VDR). 
GG genotype of the rs1800795 polymorphism in IL-6 genes triggers periodontal 
tissue destruction, while on the contrary genotypes GC and CC seem to act as 
protective agents. 
In IL-10 genes polymorphism rs1800872 CC genotype is protective against PD, while 
genotypes AA and AC are predisposing factors. 
In VDR TT genotype of the polymorphism rs731236 is a predisposing agent, while 
genotypes TC and CC are protective. 
A total number of 34 patients affected by RA were recruited into the current study, 
24 females and 10 males. Among them, 13 patients were undergoing therapy with 
the biopharmaceutical drug Etanercept, an antibody directed against TNF-α and 
inhibiting it acting as a soluble receptor (group 1). 
14 individuals were undergoing treatment with Methotrexate (group 2), an 
immunosuppressant drug with more side effects than Etanercept, while 7 patients 
were not under any treatment protocol and were included into the control group 
(CTRL). 
Statistical analysis was performed to compare genetic predisposition to PD in each 
patient with rheumatic parameters, in order to check any interaction between host 
susceptibility to periodontitis and genetic predisposition and clinical features  of the 
concurrent RA. 
IL-6, IL-10 and VDR genes polymorphisms were compared with collected data on RF, 
CCP, DAS-28 and HLA-BDR1. 
 165 
 
IL-6 did not turn out to be significantly associated with any of the rheumatic 
parametrs (p=0,22; p=0,16; p=0,11; p=0,66). However, it should be considered that 
only 3 patients expressed the protective polymorphism of the gene, while 31 
showed a predisposing polymorphism. The two groups were not equilibrate, so it 
was impossible to establish or deny any connection between IL-6 and Rheumatoid 
Arthritis. 
The same consideration should be done for VDR (p=0,24; p=0,45; p=0,33; p=0,42), 
but also in this case 28 individuals expressed a predisposing polymorphism of the 
gene while only 6 showed the protective variant, so the two subgroups were 
quantitatively not homogeneous. 
In addition, while there was not any link between IL-10 and RF, DAS-28 and HLA 
(p=0,06; p=0,36; p=0,22), a statistical significant correlation was detected between 
IL-10 and the anti-citrullinated protein’s antibody (CCP): the presence of CCP in the 
bloodstream was related to the presence of protective polymorphism CC in IL-10 
genes, showing an opposite tendency in this case (p=0,02). 
This connection should be further investigated, since recent papers have shown that 
IL-10 injected into joints affected by RA seems to decrease inflammation and thus 
is linked to biopharmaceuticals to strenghten drug efficacy. 
Comparison of periodontal polymoprhisms among them pointed out that IL-6 and 
IL-10 are strictly connected (p=0,014), being the predisposing polymorphism GG of 
IL-6 expressed together with predisposing polymorphisms AC and AA of IL-10. 
These two cytokines in periodontal disease are not genetically independent, since 
they both tend to be active together towards predisposition or protection against 
PD. 
Comparative non-parametric analysis among rheumatic data show obvious 
correlation between them (RF vs CCP p=0,00; RF vs HLA p=0,00). However, we could 
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confirm data reported in the literature, even though anti-citrullinated protein 
antibody (CCP) was the only one expressing statistical significance with all other 
parameters, including the clinical score DAS-28 (CCP vs HLA p=0,00; CCP vs DAS-28 
p=0,04). It means that CCP is the most useful element in the bloodstream which 
provides information about disease activity or severity. On the contrary, the other 
parameters did not show any correlation with the clinical features collected by DAS-
28 (RF vs DAS-28 p=0,14; HLA-DBR1 vs DAS-28 p=0,74). 
Sex represented an important feature of statistical analysis. 
RA is known to be more associated with females than males (3:1 ratio). While there 
was not any correlation with IL-6 and VDR periodontal polymorphisms (p=0,34 and 
p=0,58 respectively), a correlation was found out with IL-10 (p=0,046), being the 
predisposing polymoprhisms AC and AA expressed more in males than in females.  
Considering that females expressed RF (p=0,02) and CCP (p=0,56, almost statistically 
significant) to a major content, these data confirm those reported before between 
IL-10 and CCP. It seems than males express more IL-10 and less CCP, while on the 
contrary females express more CCP and less IL-10, being IL-10 an interesting agent 
to be used for systemic therapy against RA. Furthermore, IL-10 periodontal 
polymoprhism appears to be useful in this association. 
After the analysis of genetic and laboratory data was performed, the statistical 
analysis focused on the role of periodontal inflammation and microbioma and their 
role in RA. 
Periodontal screening record (PSR) was registered for every patient and PSR=3 was 
considered the threshold according to which patients were subdivided into two 
groups: individuals with periodontitis and patients with healthy conditions. 
Microbiological analysis was performed to establish the mean load of 
Porhyromonas gingivalis (PG), Tannerella forsythensis (TF), Treponema denticola 
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(TD), Fusobacterium nucleatum (FN) and Campylobacter rectus (CR) in periodontal 
pockets and gingival sulcus of recruited patients. 
There was not any statistically significant difference between the microbioma 
composition in patients with PSR <3 and PSR > 3 (PG p=0,09; TF p=0,88; TD p=0,25; 
FN p=0,24; CR p=0,41). It means that the clinical status of gingival tissues is not 
directly correlated to which bacteria colonize periodontal pockets. 
Afterwards, the comparison between the bacterial mean load and rheumatic 
parameters demonstrated that while there is a strong relationship between the 
“red complex” bacteria and the systemic condition in RA and disease intensity, 
“orange complex” bacteria are equally distributed and not influenced by RA. 
Rheumatoid Factor revealed a positive correlation with the presence of Tannerella 
forsythensis and Treponema denticola, while It did not show significative features 
of correlation with other bacteria. 
Anti-citrullinated protein’s antibody was significantly connected with the presence 
of Porphyromonas gingivalis, Tannerella forsythensis and Treponema denticola, 
while it did not show either a relationship with Fusobacterium nucleatum or with 
Campylobacter rectus. 
CCP turned out to be a very precious parameter in monitoring RA activity and 
correlating rheumatic conditions to periodontitis. The “red complex” bacteria were 
influenced by the presence of an increased intensity in Rheumatoid Arthritis, while 
on the contrary the “orange complex” bacteria were not related to systemic 
conditions in RA. 
DAS-28 was associated with the presence of all bacteria and it showed how an 
increased clinical and instrumental activity recorded in RA leads to a worsened 
condition within oral microbioma and consequent infection from pathogens (PG 
p=0,01; TF p=0,02; TD p=0,04; FN p=0,01; CR p=0,01). 
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Conversely, HLA-DBR1 was not linked to alteration in oral microbioma composition 
(PG p=0,73; TF p=0,91; TD p=0,64; FN p=0,48 and CR p=0,45). 
Finally, the last statistical analysis conducted on the microbiologic composition of 
dental plaque in the three groups of patients undergoing therapy with etanercept 
(group 1), metothrexate (group 2) and patients who were not on medical treatment 
(group 3) revealed that therapy with Methotrexate, an antisuppressant drug, 
determines the presence of “red complex” bacteria more than therapy with 
etanercept (PG p=0,02; TF p=0,00; TD p= 0,01) while there was not any difference 
in the composition of “orange complex” bacteria (FN p=0,85; CR p=0,06). 
 
At the end of the study, different conclusions can be drawn: 
 
1) a connection between anti-citrullinated protein antibody and 
periodontal expression of IL-10 genes’ polymorphisms was found, 
with IL-10 protecting tendency against periodontal disease incresing 
when CCP are found in bloodstream. This correlation suggests a 
possible role of IL-10 in Rheumatoid Arthritis. 
2) IL-6 and IL-10 polymorphisms are strictly associated: when IL-6 
expresses predisposing genes to periodontal disease, the same does 
IL-10. These two cytokines are not genetically independent. 
3)  CCP proved the most useful bloodstream parameter to be correlated 
with Rheumatoid Arthritis activity. CCP appears to be associated with 
all other rheumatic parameters, including the DAS-28 clinical and 
instrumental score for measuring disease activity in RA. 
4) Males express IL-10 predisposing genes to periodontal disease more 
than females, while females show a greater tendency to express 
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Rheumatoid Factor and anti-citrullinated protein antibody. This 
opposite behaviour corroborates the idea of a correlation between 
IL-10 and Rheumatoid Arthritis which should be studied in depth. 
5) The presence of the bacterial “red” and “orange” complexes are not 
related to Periodontal Score Recording, thus simple clinical 
evaluation of gingival tissues is not sufficient to assess the related risk 
of periodontits. 
6) The “red complex” bacteria Porphyromonas gingivalis, Tannerella 
forsythensis and Treponema denticola are more expressed when 
rheumatic indices are found out in the bloodstream, especially CCP. 
On the contrary, the bacterial “orange complex” composed of 
Fusobacterium nucleatum and Campylobacter rectus is not 
associated with rheumatic scores. These findings suggest the role of 
Rheumatoid Arthritis in favouring more aggressive forms of 
periodontitis. 
7) Therapy with Methotrexate is statistically associated with an 
increased presence of bacteria from the “red complex” compared 
with Etanercept. 
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            6. FINAL DISCUSSION AND CONCLUSIONS 
 
        6.1 DISCUSSION 
 
The main purpose of this clinical trial was to analyze the role of saliva and crevicular 
fluid in the pathogenesis, diagnosis and therapy of several systemic diseases, like 
chronic gastritis and Rheumatoid Arthritis or of the most common oral pathologies, 
Oral Lichen Planus and Burning Mouth Syndrome. 
Salivary and gingival fluids were chosen because recent findings in the international 
literature have strongly suggested their role as potential diagnostic tools, since they 
contain many biomarkers and cytokines useful to diagnose several diseases at an 
early stage [6]. Many authors recommend that oral fluids be thoroughly 
investigated, as they can become valid substitutes for blood test [10]. 
However, collecting homogeneous samples of saliva is very difficult and there is a 
lack of standardized protocols. Furthermore, saliva is strongly influenced by many 
variables, among which only a few can be directly controlled by the dental clinician, 
like the time of day when the test takes place, exposition to light, dental chair 
position and environmental temperature [13]. 
On the contrary, sex, age, body weight, salivary glands anatomy, physical health, 
mental health and xerogenic drugs are independent parameters which may lead to 
alterations in the composition and quantity of oral fluids, but can’t be modified by 
the dental physician. 
Besides, crevicular fluid, which is completely different from saliva and is more 
similar to interstitial fluid, is more difficult to examine since gingival tissues only 
produce a small quantity per day when healthy (0,5-2,5 ml) [17]. 
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In this experimental work oral fluids were collected from an overall number of 240 
patients for quantitative, molecular and/or microbiological investigation. 
Unstimulated whole-mouth saliva was preferred as diagnostic fluid because the 
potential alteration caused by using different types and intensities of reflex 
stimulation could be avoided [18]. 
To obtain a suitable sample of unstimulated saliva the spitting method was adopted. 
Patients sat on the dental chair and then bent their head forward. They had to spit 
every minute avoiding swallowing for 5-15 minutes. Ejected saliva was collected in 
a sterile tube or funnel. 
However, in some cases, it was useful to measure the stimulated salivary flow, and 
this was made by adding some drops of citric acid 2% solution into their mouth and 
subtracting the total amount of the stimulating solution from the total amount of 
ejected saliva. This was the case of the first study described in this dissertation: “Low 
basal salivary flow and Burning Mouth Syndrome: new evidence in this enigmatic 
pathology”. 
Burning Mouth Syndrome (BMS) is a condition characterized by a sensation 
described by patients as stinging and burning that affects the oral mucosa in the 
absence of clinical or laboratory data to justify these symptoms [21]. This condition 
principally affects women with a ratio of appoximately 4:1; this difference between 
the sexes might be explained by biological, psychological and sociocultural factors, 
even though such aspects have not been defined yet. The pathophysiology of 
idiopathic burning pain is unclear and has generated controversy over the years. 
The aetiopathogenesis seems to be complex, and in a large number of patients, is 
most likely to involve an interaction between local, systemic and/or psychogenic 
factors.  
Particular emphasis has been placed on concurrent symptoms of xerostomia. The 
role of saliva and environmental factors has been investigated, including salivary 
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gland dysfunction as a contributory factor in BMS, but contradictory findings have 
also been reported in the literature. 
In the above mentioned study the basal and stimulated flows in a group of 44 
patients with BMS were measured and then compared with an oral lichen planus 
group (OLP) of 27 patients and a control group (CTRL) of 40 patients. 
 
 
Plot 18: 44 BMS patients were recruited into the 1st study and compared with an 
OLP group of 27 patients and a CTRL group of 40 patients 
 
The OLP group was not included for its statistical significance per se, as a BMS and 
a CTRL group were sufficient to compare the outcomes. However, OLP is the most 
frequent chronic inflammatory condition or oral mucosae (see below) and the 
normal values registered within this group highlighted the peculiarity of the 
outcomes registered in BMS patients. 
As a matter of fact, the outcomes of the research demonstrated a very low basal 
salivary flow in BMS patients compared with the other two groups, but the 
stimulated salivary flow was similar in BMS patients (p=0,002). 
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Table 3: mean salivary flow values and following statistical analysis 
This leads to the hypothesis that salivary function is preserved in Burning Mouth 
Syndrome, but that chronic intake of antihypertensive, anxyolitic and 
antidepressant drugs on one side and the contextual presence of psychological 
behaviour distress on the other side could influence the basal tone of those salivary 
glands responsible for the basal flow function, such as the submandibular, 
sublingual and the minor salivary glands. 
This study non only contributes to a better understanding of the role of saliva in the 
pathogenesis of this enigmatic pathology, but also points out how the central 
nervous system and associative cortices may strongly influence the salivary flow 
rate, which is the main contributory factor to determine salivary composition. 
Salivary composition is fundamental to maintain stable healthy conditions in the 
oral cavity.  
Saliva fulfills defensive functions, thanks to the presence of many enzymes, among 
which lysozyme, lactoperoxidase, lactoferrin and antimicrobial peptides. 
The antimicrobial peptides (AMPs) are polypeptides of less than 100 amino acids 
detectable in host defense settings, and that have antimicrobial activity at 
physiological concentrations under conditions prevailing in the tissues of origin [51].  
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In humans AMPs can be classified into two families that have been thoroughly 
characterized, the cathelicidins and the defensins. 
The only cathelicidin described in humans has been named human cationic 
antimicrobial  peptide hCAMP18, which is transformed into a small peptide, known 
as LL-37, by a serine protease expressed in neutrophils. hCAMP18/LL-37 cathelicidin 
is produced by different cell types, including myeloid cells, neutrophils, mast cells, 
monocytes, epithelial cells of the colon, urinary tract annd respiratory mucous 
membranes [58]. 
Defensins are a family of small-sized ß-chained peptides whose molecular weight 
ranges from 3,5 to 4,5 kDa and include 6 cysteine residues which can create disulfide 
bridges. ß-defensins, expecially HBD-2, has been studied in the oral cavity. HBD-2 is 
an inducible peptide and its production is stimulated by proinflammatory cytokines, 
such as IL-1, TNF-α and by bacterial products [72]. 
AMPs perform a direct antimicrobial activity thanks to their electrostatic interaction 
with the negatively charged phopsholipids on bacterial membranes, but they also 
serve an immunomodulatory function. They act as chemoattractive agents on 
monocytes, neutrophils and CD4+ lymphocytes and stimulate the production of 
other chemokines. 
It is debated whether functional impairment or enhancement of AMPs can influence 
the clinical course of several diseases, among which infective and chronic 
inflammatory pathologies. 
The second study in this dissertation, entitled “Human ß2-defensin in Oral Lichen 
Planus and Burning Mouth Syndrome”, focused on the possible role of defensins in 
the pathogenesis and maintenance of the most common autoimmune disorder of 
the oral cavity, Oral Lichen Planus (OLP). 
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OLP is a common, chronic cutaneous disease which often affects the oral mucosa. 
Most of patients with OLP are middle-aged adults, with a 3:2 ratio of women to 
men. It is believed that about 1% of the population may have this condition. In the 
oral cavity, the disease develops with lesions characterized by radiating, velvety, 
thread-like white/grey papules arranged in a linear, annular or retiform pattern 
forming typical lacy, reticular patches, rings and streaks over the buccal mucosa 
and, to a lesser extent, on the lips, tongue and palate. These lesions trigger no 
significant symptoms in the majority of patients, while in others there may be a 
complaint of a burning sensation in the involved areas [76]. 
The clinical forms can be grouped into two families: the “White” OLP, which includes 
asymptomatic papular, reticular and hyperplastic forms, and the “Red” OLP, which 
is characterized by a clinical evidence of inflammation and may be represented by 
atrophic, erosive, ulcerative and bullous forms. 
In this study samples collected from the saliva and crevicular fluid of a group of 35 
patients were analyzed with ELISA protocol the presence of HBD-2. Among them, 
17 patients were histologically diagnosed with OLP, 9 with BMS and 9 were enrolled 
as a control group (CTRL). 
 
Plot 19: 17 OLP patients were recruited into the 2nd study and registered values of 
HBD-2 were compared with those of a group of 9 BMS patients and a control 
group of 9 patients 
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Furthermore, a dental physician classified the clinical forms of OLP into 10 “White” 
and 7 “Red” OLP forms based upon their clinical appearance. 
While there were not any statistically significant differences between the groups, 
both for the OLP and BMS groups compared with the CTRL group, the study pointed 
out the role of HBD-2 in the maintenance and intensity of the inflammatory 
component of OLP. 
Patients affected by OLP showed a dycotomic distribution of values: 10 of them 
showed similar values to those encountered in the other two groups, while 7 
resulted in expressing increased levels of HBD-2. There was a high correlation 
between the clinical and biomolecular independent classification of patients 
(p=0,001), and the expression of HBD-2 was higher in the “red” OLP subgroup than 
in the “white” one (p=0,000). HBD-2 could be used as a parameter to monitor the 
degree of disease activity and inflammation, and for this reason research into the 
role of salivary and gingival defensins in the pathogenesis of autoimmune oral 
disease requires further investigation. 
Saliva in the oral cavity does not merely have a defensive function, but it also acts 
as a key factor in lubrication of oral mucosae, calcium homeostasis and digestion. 
Saliva is the first enzymatic liquid which is encountered in the gastrointestinal tube 
and acts synergystically with other secretions. Saliva contains α-amylase, which is 
responsible for degradation of the 1-4 glycosidic bond in starches. When saliva is 
swallowed and reaches the stomach through the oesophagus, α-amylase is 
inactivated by gastric secretion. 
There are many links between the oral cavity and the stomach, considering that 
they belong to the same apparatus, the gastrointestinal tube. 
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One of the most interesting finding is the presence of Helicobacter pylori in the oral 
cavity. 
Helicobacter pylori (HP) is a widespread bacterium, which is associated with chronic 
gastritis in 90% of cases, but it has been also described in gastric cancer. Despite the 
fact that infection incidence has decreased in recent years, about half of the world’s 
population is still infected. Furthermore, therapy resistance and relapses represent 
a threatening issue to be taken into account [81]. 
In 1994 the WHO classified HP as a carcinogenic agent, and IARC has included it in 
the group 1 list of carcinogens [85]. 
To make a correct diagnosis of gastric infection, the C-Breath Test Urea (C-BTU) is 
used, since it measures the bacterial urease activity in breath. 
Triple therapy, including a Proton Pump Inhibitor (PPI) plus two antibiotics, such as 
clarythromycin and amoxicillin or metronidazole, is the first treatment of choice. 
In recent years, the prevalence of resistant bacterial strains has worldwide called 
the attention of clinicians to the worrisome increase in the rates of unsuccessful 
therapeutic outcomes. In fact, the results of recent studies have shown that 
documented eradication rates are at their lowest level in history. This could be due 
to incomplete elimination of HP, leading to recrudescence of the same strain, or to 
reinfection with a new strain, with recrudescence being the more common cause of 
relapses. 
These features made clinicians put forward the possibility of an extra-gastric 
reservoir of infection [95]. The presence of HP in the oral cavity was firstly 
discovered in 1989 and following studies detected it in dental plaque, saliva, tongue, 
tonsil tissue and root canals [98]. A meta-analysis published in 2011 [100] reported 
a strong connection between the presence of HP in the oral cavity and in the 
stomach. However, triple eradication therapy has no or little effect and acts as a 
 179 
 
causal factor in the recurrence of HP infection. The introduction of PCR-RT 
technique allowed researchers to detect HP when it is highly present in saliva or 
dental plaque. 
The third study described in this dissertation, entitled “Helicobacter pylori in 
periodontal pockets and saliva: a possible role in gastric infection relapses? A 
preliminary study in Northern Italy” proposed evaluating the presence of oral HP in 
a group of patients who underwent examination for gastric HP infection.  
A total number of 60 patients were recruited into this study, 30 with a positive 
diagnosis of gastric infection and 30 with a negative diagnosis after the C-BTU 
examination. 
 
 
Plot 20: patients with positive results at C-BTU test were recruited into the 3rd 
study together with 30 patients who tested negative  
 
 A dental clinician performed periodontal evaluation and collected salivary and 
crevicular fluid samples. PCR-RT analysis was conducted to detect the presence of 
HP in collected samples. 
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Even though there was not any statistically significant difference among the two 
groups as to the total amount of HP in saliva (p=0,372) or crevicular fluid (p=0,604; 
p=0,326; p=0,368; p=0,731), it should be considered that they are two completely 
different methods with different specificity and sensibility and provide a picture at 
the same moment of two different anatomic districts. However, a remarkable 
datum was detected as regards HP behaviour in the oral cavity: patients affected by 
periodontal disease showed higher values of HP. 
These outcomes suggest that HP is present in the oral cavity and that it is not related 
to gastro-esophageal reflux or stomach load, like some authors have claimed so far, 
but it has a direct role within the affected periodontal tissues. 
Recent findings in the literature show there is an immunological relationship 
between HP and Campylobacter rectus, and clearly indicate that one of the shared 
antigens is a GroEL protein, able to influence the onset and development of 
periodontal disease through its biological activity [107]. Furthermore, the 
microaerophilic and acid environment of periodontal pockets provides suitable 
conditions for growth and proliferation of HP. Considering that HP was originally 
called Campylobacter-like bacterium, it is advisable to regard HP as a colonizing 
bacterium of periodontal tissues when they are affected by periodontal disease, and 
when a biofilm with different species can increase the efficacy of the single species 
thanks to gene exchanges and signaling pathways among the different bacterial 
subtypes. 
In addition, HP in periodontal tissues is not confined to periodontal pockets, but 
migrates from the gingival sulcus into saliva, as it was demonstrated by comparing 
the presence of the bacterium in the saliva of periodontal patients with the values 
measured in healthy individuals (p=0,05). 
Thus, periodontal disease stimulates a suitable environment for HP, the periodontal 
pocket. At this site the bacterium finds favourable conditions to thrive in sinergy 
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with other bacteria. Once it has reached a sufficient amount of load, the bacterium 
migrates from the sulcus into the oral cavity and enters saliva. Since saliva is 
swallowed and flows into the stomach, the oral cavity consequently becomes an 
extra-gastric reservoir of HP which reaches the stomach thanks to deglutition. 
Whether salivary content in HP may cause gastric infection relapses should be 
studied in depth by reassessing the 30 C-BTU positive patients after eradication 
therapy, and by repeating both C-BTU and periodontal examinations to collect data 
for statistical analysis. 
Another issue which has drawn attention of the scientific community is the 
relationship between salivary and crevicular fluids biomarkers and periodontal 
disease. 
Periodontal disease is with dental caries one of the two most common diseases of 
the oral cavity. It affects about 80% of the world’s population. The disease involves 
the supporting structures of the periodontium, like gingiva, periodontal ligament 
and the alveolar bone. The final stage of the disease is the loss of dental elements 
by exfoliation. Genetic predisposition may have an important role in establishing 
whether an individual is prone to be affected [130], but dental plaque is the causal 
factor. The clinical course of the disease depends on host’s immunitary defenses 
and the bacterial load. Dental plaque contains more than 300 different bacterial 
species, but only a few have been associated with a high risk of developing 
periodontal disease. The connection among bacteria within the biofilm is not 
random. Six species have been found to be strictly linked and responsible for the 
clinical development of the disease: Aggregatibacter actinomycetemcomitans, 
Porhyromonas gingivalis, Tannerella forsythensis, Treponema denticola, which 
belong to the “red complex” of pathogens, and Fusobacterium nucleatum and 
Campylobacter rectus, which belong to the “orange complex”.  
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Among cytokines the ones which may have a significant role in periodontal 
inflammatory disease are IL-1, TNF-α, IL-6, IL-10 and VDR [134][135].  
Salivary and crevicular fluid biomarkers proved to be useful in diagnosing and 
monitoring some systemic diseases, like diabetes mellitus, cardiovascular disease, 
viral infections, pancreatic cancer, breast cancer, lung cancer, prostate cancer and 
Rheumatoid Arthritis. 
In the fourth study presented in this dissertation, “Rheumatoid Arthritis therapies 
and Periodontal disease: any correlation?” the proposal is to appraise the 
connection between Rheumatoid Arthritis (RA) and Periodontal disease (PD). 
34 patients with Rheumatoid Arthritis were recruited into the above mentioned 
study, all of them being affected by RA. 13 were under therapy with anti TNF-α 
biopharmaceutical Etanercept (group 1), 14 were undergoing treatment with 
immunosuppressant Methotrexate (group 2) and 7 were recruited as control group 
(group 3) without any course of treatment. 
 
 
Plot 21: 34 patients affected by Rheumatoid Arthritis were recruited into the 4th 
study. Among them, 13 were undergoing therapy with Etanercept (group 1), 14 
with Methotrexate (group 2) and 7 were recruited as a control group (group 3). 
0
5
10
15
Etanercept Methotrexate Control
Recruited patients
Etanercept Methotrexate Control
 183 
 
The rheumatologist collected data about the disease intensity and laboratory 
findings. Among haematochemical analysis, Rheumatoid Factor (RF), anti-
citrullinated protein antibody (CCP) and HLA-BDR1 were prescribed. The DAS-28 
questionnaire for clinical and laboratory scores was completed to determine the 
degree of RA severity. 
Then the dental clinician performed a dental and periodontal examination, 
collecting samples of gingival liquid for genetic and microbiologic analyses. 
Statistical analysis was carried out to compare the genetic and microbiologic 
periodontal results with RA systemic indeces. 
There were some interesting correlations between Rheumatoid Arthritis and 
Periodontal Disease: a link between CCP and expression of IL-10 genes protecting 
polymorhisms against PD was found (p=0,02), suggesting a possible role of IL-10 in 
Rheumatoid Arthritis. In addition, IL-6 and IL-10 polymorphisms were strictly related 
(p=0,014): when IL-6 expresses predisposing genes to periodontal disease, the same 
does IL-10. These two cytokines are not genetically independent. Males express IL-
10 predisposing genes to PD more than females do (p=0,05), while females show a 
greater tendency to express RF and CCP (p=0,02). This opposite behaviour confirms 
the correlation between IL-10 and RA and further research should be carried out.  
CCP proved to be the most useful blood parameter to be correlated with 
Rheumatoid Arthritis activity and was associated with all ther rheumatic 
parameters, including DAS-28. 
Microbiological analysis revealed that the “red-complex” bacteria Porphyromonas 
gingivalis, Tannerella forsythensis and Treponema denticola are more expressed 
when Rheumatoid Arthritis indices are detected in the bloodstream, mostly CCP. On 
the contrary, the “orange-complex” bacteria Fusobacterium nucleatum and 
Campylobacter rectus are not associated with Rheumatic scores. These findings 
suggest a role of RA in favouring more aggressive forms of periodontitis. Finally, 
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therapy with methotrexate is statistically associated with an increasing presence of 
red-complex bacteria when compared to Etanercept (p=0,02; p=0,00; p=0,01). 
 
 
6.2 CONCLUSION AND FUTURE PERSPECTIVES 
The experimental work described in this PhD thesis focused on the role of saliva and 
crevicular fluids as diagnostic tools useful to detect systemic pathologies, 
understand the complex mechanism of the correlation between periodontal disease 
and systemic infective and autoimmune diseases and explain the underlying 
pathogenesis beyond very common oral disorders, like Oral Lichen Planus and 
Burning Mouth Syndrome. 
At the end of this dissertation, it can be adfirmed that oral fluids will certainly 
substitute for blood test, when standardized procedures and reliable data 
interpretation are provided by the scientific community. 
To sum up, the outcomes of the reported studies demonstrated: 
-  a very low basal salivary flow in Burning Mouth Syndrome (BMS) 
patients compared with other patients, but equal stimulated flow. 
This study suggests new topics for further investigation in order to 
explain puzzling pathologies such as Burning Mouth Syndrome. 
Besides, it points out how emotions and psychosomatic distress can 
influence the production of saliva with consequences on oral health. 
Additional studies are required to better investigate this 
phenomenon through the use of more specific salivary tests and 
funtional neurophysiological imaging.  
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-  the role of Human ß2-defensin in the pathogenesis of Oral Lichen 
Planus (OLP), showing how its most inflamed forms express a larger 
amount of HBD-2, thus revealing the significance of this small peptide 
in chronic inflammation. More studies are necessary to evaluate the 
role of Human ß3-defensin in chronic inflammation and the 
behaviour of both HBD-2 and HBD-3 in periodontal disease, so as to 
produce low weight polymers of Hyaluronic acid which could be 
prescribed to treat periodontitis and strenghten causal and 
mechanical therapies. 
- the presence of Helicobacter pylori (HP) in the oral cavity as an extra-
gastric reservoir in periodontally affected gums. In addition, the 
increased load of HP detected in periodontitis is not confined to 
periodontal pockets, but migrates from the gingival crevice to the 
stomach through swallowed saliva. Patients diagnosed as positive for 
gastric infection through the C-BTU will undergo eradication therapy 
and will be reassessed again after 6 months both for the gastric and 
oral infection. If patients with relapses are statistically associated 
with an increased oral HP load, it will be possible to establish the true 
role of extra-gastric resorvoir of HP in gastric relapses, a topic which 
is becoming crucial worldwide. 
- there are many correlations between periodontal disease (PD) and 
Rheumatoid Arthritis (RA); IL-10 antinflammatory action should be 
thoroughly investigated to better understand the possible use in next 
generation drugs for periodontal disease.   
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